SciSparc (SPRC) 20-F 30 Mar 21 2020 FY Annual report (foreign) Financial data

Document And Entity Information

Document And Entity Information	12 Months Ended
	Dec. 31, 2020shares
Document Information Line Items
Entity Registrant Name	SciSparc Ltd./ADR
Document Type	20-F
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding	145,148,593
Amendment Flag	false
Entity Central Index Key	0001611746
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Non-accelerated Filer
Entity Well-known Seasoned Issuer	No
Document Period End Date	Dec. 31, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	FY
Entity Emerging Growth Company	true
Entity Shell Company	false
Entity Ex Transition Period	false
Document Annual Report	true
Document Shell Company Report	false
Document Transition Report	false
Entity File Number	001-38041
Entity Incorporation, State or Country Code	L3
Entity Interactive Data Current	No

Consolidated Statements of Fina

Consolidated Statements of Financial Position - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
CURRENT ASSETS:
Cash	$ 1,946	$ 870
Restricted deposit	10	10
Other accounts receivable	594	75
Total current assets	2,550	955
NON-CURRENT ASSETS:
Restricted deposit		24
Property and equipment, net	11	175
Total non-current assets	11	199
Total assets	2,561	1,154
CURRENT LIABILITIES:
Credit from others		67
Trade payables	556	864
Other accounts payable	34	108
Short-term loan	188
Warrants	353	7
Total current liabilities	1,131	1,046
NON-CURRENT LIABILITIES:
Lease liability		94
EQUITY ATTRIBUTABLE TO EQUITY HOLDERS OF THE COMPANY:
Share capital and premium	49,040	45,636
Reserve from share-based payment transactions	4,315	4,862
Warrants	2,207	464
Foreign currency translation reserve	497	497
Transactions with non-controlling interests	559	261
Accumulated deficit	(55,188)	(51,706)
Total equity	1,430	14
Total liabilities and equity	$ 2,561	$ 1,154

Consolidated Statements of Prof

Consolidated Statements of Profit or Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Profit or loss [abstract]
Research and development expenses	$ 649	$ 1,639	$ 2,710
General and administrative expenses	1,902	2,469	4,371
Other expenses	742		160
Operating loss	3,293	4,108	7,241
Finance income	(630)	(305)	(828)
Finance expenses	872	676	121
Loss continuing operations	3,535	4,479	6,534
Loss from discontinued operations, net		207	2,415
Loss	3,535	4,686	8,949
Attributable to:
Equity holders of the Company (continuing operations)	3,482	4,479	6,534
Equity holders of the Company (discontinued operations)		315	1,989
Non-controlling interests	53	(108)	426
Profit loss	$ 3,535	$ 4,686	$ 8,949
Basic loss per ordinary share attributable to equity holders of the Company:
Loss from continuing operations (in Dollars per share)	$ 0.10	$ 0.60	$ 1
Loss from discontinued operations (in Dollars per share)		0.04	0.20
Basic loss per ordinary share to equity holders total (in Dollars per share)	0.10	0.64	1.20
Diluted loss per ordinary share attributable to equity holders of the Company:
Loss from continuing operations (in Dollars per share)	0.11	0.60	1
Loss from discontinued operations (in Dollars per share)		0.04	0.20
Diluted loss per ordinary share to equity holders total (in Dollars per share)	0.11	0.64	1.20
Basic loss per ADS attributable to equity holders of the Company:
Loss from continuing operations (in Dollars per share)	13.49	84	140
Loss from discontinued operations (in Dollars per share)		5.60	28
Basic loss per ADS attributable to equity holders total (in Dollars per share)	13.49	89.60	168
Diluted loss per ADS attributable to equity holders of the Company:
Loss from continuing operations (in Dollars per share)	14.90	84	140
Loss from discontinued operations (in Dollars per share)		5.60	28
Diluted loss per ADS attributable to equity holders total (in Dollars per share)	$ 14.90	$ 89.60	$ 168

Consolidated Statements Compreh

Consolidated Statements Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Consolidated Statements Comprehensive Loss [Abstract]
Loss	$ 3,535	$ 4,686	$ 8,949
Amounts that will not be reclassified subsequently to profit or loss:
Adjustments arising from translating financial statements from functional currency to presentation currency			285
Total components that will not be reclassified subsequently to profit or loss			285
Total other comprehensive loss			285
Total comprehensive loss	3,535	4,686	9,234
Attributable to:
Equity holders of the Company (continuing operations)	3,482	4,479	6,819
Equity holders of the Company (discontinued operations)		315	1,989
Non-controlling interests	53	(108)	426
Comprehensive loss	$ 3,535	$ 4,686	$ 9,234

Consolidated Statements of Chan

Consolidated Statements of Changes in Equity - USD ($) $ in Thousands		Share capital and premium	Reserve from share-based payment transactions	Warrants	Transactions with non-controlling interests	Foreign currency translation reserve	Accumulated deficit	Total	Non-controlling interests	Total
Balance at Dec. 31, 2017		$ 40,424	$ 5,311		$ 261	$ 782	$ (38,389)	$ 8,389		$ 8,389
Income (loss)							(8,523)	(8,523)	(426)	(8,949)
Total other comprehensive loss						(285)		(285)		(9,234)
Total comprehensive loss						(285)	(8,523)	(8,808)	(426)	(9,234)
Non-controlling interests arising from initially consolidated company									318	318
Issue of share capital, net of issue expenses
Expiration of share options		1,506	(1,506)
Cost of share-based payment			604					604		604
Balance at Dec. 31, 2018		41,930	4,409		261	497	(46,912)	185	(108)	77
Income (loss)							(4,794)	(4,794)	108	(4,686)
Total other comprehensive loss										(4,686)
Issue of share capital, net of issue expenses	[1]	2,099						2,099		2,099
Conversion of convertible debentures (Note 13b)		1,507						1,507		1,507
Registration of the resale of warrants (Note 17e)				464				464		464
Expiration of share options		100	(100)
Cost of share-based payment			553					553		553
Balance at Dec. 31, 2019		45,636	4,862	464	261	497	(51,706)	14		14
Income (loss)							(3,482)	(3,482)	(53)	(3,535)
Warrants reclassification				(464)				(464)		(464)
Total other comprehensive loss										(3,535)
Issue of share capital, net of issue expenses	[2]	2,763		2,207				4,970		4,970
Conversion of convertible debentures (Note 13b)		3						3		3
Non-controlling interests					298			298	$ 53	351
Expiration of share options		638	(638)
Cost of share-based payment			91					91		91
Balance at Dec. 31, 2020		$ 49,040	$ 4,315	$ 2,207	$ 559	$ 497	$ (55,188)	$ 1,430		$ 1,430
[1]	Net of issue expenses of $469.
[2]	Net of issue expenses of $784

Consolidated Statements of Ch_2

Consolidated Statements of Changes in Equity (Parentheticals) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Consolidated Statements of Changes in Equity [Abstract]
Net of issue expenses	$ 784	$ 469

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Cash flows from operating activities:
Loss	$ (3,535)	$ (4,686)	$ (8,949)
Adjustments to the profit or loss items:
Depreciation and amortization	164	179	147
Loss (gain) from sale of equipment		1,223	(7)
Cost of share-based payment	91	553	604
Finance expenses (income), net	(476)	156	(748)
Impairment loss of intangible assets			273
Impairment loss of goodwill			160
Impairment of investment in associate	795
Aborted public offering costs			53
Tax benefit			(60)
Total adjustments to the profit or loss	574	2,111	422
Working capital adjustments:
Decrease (increase) in other accounts receivable	(519)	329	(99)
Increase (decrease) in trade payables	(752)	(840)	177
Increase (decrease) in other accounts payable	(75)	(736)	649
Increase(decrease) in related parties		(874)	668
Working capital	(1,346)	(2,121)	1,395
Net cash used in operating activities	(4,307)	(4,696)	(7,132)
Cash flows from investing activities:
Investment in restricted bank deposits	24	(1)	(10)
Purchase of property and equipment		(1)	(17)
Proceeds from sale of property and equipment		724	44
Proceeds from (investment in) convertible loans		546	(2,125)
Acquisition of initially consolidated subsidiary (a)			14
Net cash provided by (used in) investing activities	24	1,268	(2,094)
Cash flows from financing activities:
Proceeds from issue of share capital (net of issuance expenses) (b)	2,650	2,216
Issue of warrants (b)	2,376	682
Payment of issuance expenses related to previous period (b)	116	(30)
Interest paid on lease liability	(7)	(17)
Repayment of lease liability	(26)	(47)
Issue of convertible debentures (net of issuance expenses) (b)			1,481
Prepaid public offering costs			(36)
Repayment of short-term credit	(1,410)
Receipt of short-term credit from others, net	1,660		91
Net cash provided by financing activities	5,359	2,804	1,536
Exchange rate differences on cash in foreign currency		9	301
Exchange rate differences on translation differences on cash			(321)
Exchange rate differences, Total		(9)	(20)
Increase (decrease) in cash	1,076	(615)	(7,710)
Cash at the beginning of the period	870	1,485	9,195
Cash at the end of the period	$ 1,946	$ 870	$ 1,485

Consolidated Statements of Ca_2

Consolidated Statements of Cash Flows (Parenthetical) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
The subsidiaries’ assets and liabilities at date of acquisition:
Working capital (excluding cash)			$ 648
Property and equipment			(2,192)
Customer relationships			(307)
Deferred taxes liability			60
Goodwill			(160)
Non-controlling interests			318
Assets and liabilities at date of acquisition			(1,633)
Conversion of convertible loans			1,647
Acquisition of initially consolidated subsidiary, Total			14
(b) Significant non-cash transactions:
Conversion of debentures into share capital		$ 1,507
Issue of share capital			10
Registration of warrants		464
Unpaid issue expenses		$ 116	$ 30

General

General	12 Months Ended
	Dec. 31, 2020
Disclosure Of General Explanatory [Abstract]
GENERAL	NOTE 1:- GENERAL a. SciSparc Ltd. (formerly known as Therapix Biosciences Ltd.) (“SciSparc” or the “Company”), a pharmaceutical company, was incorporated in Israel and commenced its operations on August 23, 2004. Until March 2014, SciSparc and its subsidiaries at the time (the “Group”) were mainly engaged in developing several innovative immunotherapy products and SciSparc’s own patents in the immunotherapy field. In August 2015, the Company decided to adopt a different business strategy and began focusing on developing a portfolio of approved drugs based on cannabinoid molecules. With this focus, the Company is currently engaged in the following development programs based on Δ9-tetrahydrocannabinol (“THC”) and/or non-psychoactive cannabidiol for the treatment of Tourette syndrome and for the treatment of obstructive sleep apnea, pain, Autism Spectrum Disorder and epilepsy. The headquarters of the Company are located in the Tel Aviv, Israel. The Company changed its name from Therapix Biosciences Ltd. to SciSparc Ltd. on January 24, 2021. The Company was previously a dual-listed company, whereby it listed (a) its ordinary shares, no par value each (“ordinary shares”), on the Tel-Aviv Stock Exchange (“TASE”) from December 26, 2005 until its delisting on August 7, 2018, and (b) its American Depository Shares (“ADSs”) on the Nasdaq Capital Market (“Nasdaq”) following its initial public offering (“IPO”) on March 27, 2017, at which time it raised $13,700, until its suspension from listing, and subsequent delisting, from Nasdaq on July 2, 2020 and September 21, 2020, respectively. Following the delisting of the ADSs from Nasdaq, the Company’s ADSs were listed on the Pink Sheets and then subsequently upgraded to the OTCQB on December 8, 2020. The ADSs are currently quoted on the OTCQB under the symbol “SPRCY”. Since the IPO, the Company has had its ADSs registered with the U.S. Securities and Exchange Commission (“SEC”). All information in these financial statements regarding the ADSs presumes that all of the Company’s ordinary shares have been converted into ADSs. Each ADS represents one hundred and forty (140) ordinary shares. As of December 31, 2020, the Company had two subsidiaries, both of which are companies incorporated under the laws of Israel: (1) Brain Bright Ltd. (“Brain Bright”); and (2) Evero Health Ltd. (“Evero” and together with Brain Bright, the “Subsidiaries”). Both of the Subsidiaries are private companies, and as of the date of these financial statements, Brain Bright is an inactive company with no assets or liabilities. The Company also owns approximately 27% of the share capital of Lara Pharm Ltd. (“Lara”). Lara is a private company incorporated under the laws of Israel which, to the Company’s knowledge, does not engage in any business, and in any event, the Company does not have significant influence over Lara since it has no representation on Lara’s board of directors. The Company wrote-off the entire investment in Lara in 2015 (see Note 8a). On October 3, 2018 (the “Acquisition Date”), the Company obtained control over Therapix Healthcare Resources Inc. (“THR”), a Delaware corporation, which was established on July 31, 2018, by acquiring 82.36% of THR’s equity through the conversion of a convertible loan. On June 27, 2019, following the finalization of THR’s dissolution, completed by submitting all documents required by law (“THR’s Dissolution”), the Company deconsolidated THR (see Note 4). The consolidated financial statements of the Company for the year ended December 31, 2020, were approved on March 25, 2021 and signed on March 29, 2021 (the “Approval Date”). b. Functional currency and presentation currency: The functional currency of the Company, which is the currency that best reflects the economic environment in which the Company operates and conducts its transactions is the U.S. Dollar (“USD” or “$”), since it’s the primary currency of the economic environment in which the Company operates (see Note 2e). The consolidated financial statements are also presented in USD since the Company believes that preparing the consolidated financial statements in USD provides more relevant information to the users of the consolidated financial statements. c. The Group incurred operating losses since its incorporation, and expects to continue to incur operating losses for the foreseeable future. As of December 31, 2020, the Group had an accumulated deficit of approximately $55,188 as a result of recurring operating losses. As of the Approval Date, the Group has not yet started recognizing revenues from sales and its operations are dependent on its ability to raise additional funds from existing and/or new investors. This dependency will continue until the Group will be able to completely finance its operations by generating revenue from its products. In addition, as of the Approval Date, the Group has raised the necessary funding in order to continue its activity in the foreseeable future. As of the Approval Date, the Company had $7.78 million in cash. The Company anticipates that its cash as of December 31, 2020 will provide sufficient liquidity for more than a twelve-month period from March 29, 2021. The actual amount of cash that the Company will need to operate is subject to many factors, including, but not limited to, the timing, design and conduct of clinical trials for its drug candidates. The Company is dependent upon significant future financing to provide the cash necessary to execute its current operations, including the commercialization of any of its drug candidates. d. Public health epidemics or outbreaks could adversely impact the Company’s business. In late 2019, a novel strain of COVID-19, also known as coronavirus, was reported in Wuhan, China. While initially the outbreak was largely concentrated in China, it has now spread to several other countries, including in Israel, and infections have been reported globally. The extent to which the coronavirus impacts the Company’s operations will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration and severity of the outbreak, and the actions that may be required to contain the coronavirus or treat its impact. In particular, the continued spread of the coronavirus globally, could adversely impact the Company’s operations and workforce, including other Company’s research and clinical trials and its ability to raise capital, which in turn could have an adverse impact on the Company’s business, financial condition and results of operation. e. Definitions and Meanings: The Company - SciSparc Ltd. (formerly known as Therapix Biosciences Ltd.) The Group - SciSparc Ltd. (formerly Therapix Biosciences Ltd.) and its Subsidiaries, as detailed in Note 1a. Subsidiaries - Companies that are controlled by the Company, as defined in IFRS 10, “ Consolidated Financial Statements Associates - An entity over which the Company has significant influence, as defined in IAS 28, “ Investment in Associates and Joint Ventures Related Parties - As defined in IAS 24, “ Related Party Disclosures IAS - International Accounting Standards issued by the International Accounting Standards Board (“IASB”). IFRS - International Financial Reporting Standards issued by the IASB.

Significant Accounting Policies

Significant Accounting Policies	12 Months Ended
	Dec. 31, 2020
Disclosure of significant accounting policies [text block] [Abstract]
SIGNIFICANT ACCOUNTING POLICIES	NOTE 2:- SIGNIFICANT ACCOUNTING POLICIES The following accounting policies have been applied consistently in the financial statements for all periods presented, unless otherwise stated. a. Basis of presentation of the financial statements: These financial statements have been prepared in accordance with IFRS, as issued by the IASB. The Company’s financial statements have been prepared on a cost basis, unless otherwise indicated. The Company has elected to present the profit or loss items using the function of expense method. The financial statements are presented in USD and all values are rounded to the nearest thousand (‘000), except when otherwise indicated. b. The operating cycle: The operating cycle of the Company is one year. c. Consolidated financial statements: The consolidated financial statements comprise the financial statements of companies that are controlled by the Company (Subsidiaries). Control of a company is achieved when the Company is exposed, or has rights, to variable returns from its involvement with the investee and has the ability to affect those returns through its power over the investee. Potential voting rights are considered when assessing whether an entity has control over the other entity. The consolidation of the financial statements commences on the date on which control is obtained and ends when such control ceases. The financial statements of the Company and of the Subsidiaries are prepared as of the same dates and periods. The consolidated financial statements are prepared using uniform accounting policies by all companies in the Group. Significant intra-Group balances and transactions and gains or losses resulting from intra-Group transactions are eliminated in full in the consolidated financial statements. Non-controlling interests in subsidiaries represent the equity in subsidiaries not attributable, directly or indirectly, to a parent. Non-controlling interests are presented in equity separately from the equity attributable to the equity holders of the Company. Profit or loss and components of other comprehensive income are attributed to the Company and to non-controlling interests. Losses are attributed to non-controlling interests even if they result in a negative balance of non-controlling interests in the consolidated statement of financial position. d. Discontinued operations: A discontinued operation is a component of the Company that either has been disposed of or is classified as held for sale. The operating results relating to the discontinued operation are presented separately in profit or loss, net of the tax effect. e. Functional currency and foreign currency: 1. Functional currency and presentation currency: Effective on October 1, 2018, due to changes in certain economic facts and circumstances, the functional currency of the Company was changed from the New Israeli Shekel (“NIS”) to USD. Thus, the functional and reporting currency of the Company is the USD. In determining the appropriate functional currency that should be used, the Company followed the guidance in IAS 21, “ The Effects of Changes in Foreign Exchange Rates All resulting translation differences until October 1, 2018, following the fact that the reporting currency was different than the functional currency, were recognized as a separate component of other comprehensive income (loss) in equity “foreign currency translation reserve.” The functional currency of THR up until THR’s Dissolution, was also USD. 2. Transactions, assets and liabilities in foreign currency: Transactions denominated in foreign currency (other than the functional currency) are recorded on initial recognition at the exchange rate at the date of the transaction. After initial recognition, monetary assets and liabilities denominated in foreign currency are translated at each reporting date into the functional currency at the exchange rate at that date. Non-monetary assets and liabilities denominated in foreign currency and measured at fair value are retranslated into the functional currency using the exchange rate prevailing at the date when the fair value was determined. Non-monetary assets and liabilities measured at cost are translated at the exchange rate at the date of the transaction. f. Business combinations and goodwill: Business combinations are accounted for by applying the acquisition method. The cost of the acquisition is measured at the fair value of the consideration transferred on the acquisition date with the addition of non-controlling interests in the acquiree. In each business combination, the Company chooses whether to measure the non-controlling interests in the acquiree based on their fair value on the acquisition date or at their proportionate share in the fair value of the acquiree’s net identifiable assets. Direct acquisition costs are carried to the statement of profit or loss as incurred. Goodwill is initially measured at cost which represents the excess of the acquisition consideration and the amount of non-controlling interests over the net identifiable assets acquired and liabilities assumed. If the resulting amount is negative, the acquirer recognizes the resulting gain on the acquisition date. g. Restricted deposits: A restricted deposit is cash invested in a short-term deposit (between three months and one year) or in a long-term deposit (with a maturity of more than one year from the date of investment). Restricted deposits are designated to secure the Company’s office facilities lease agreements and its credit cards. h. Property and equipment, net: Property and equipment are measured at cost, including directly attributable costs, less accumulated depreciation, accumulated impairment losses and any related investment grants and excluding day-to-day servicing expenses. Depreciation is calculated on a straight-line basis over the useful life of the assets at annual rates as follows: % Mainly % Lab equipment 6-50 33 Computers 33-50 33 Office furniture and equipment 20-33 25 Motor vehicles 55 - Leasehold improvements see below - Leasehold improvements are depreciated on a straight-line basis over the shorter of the lease term (including the extension option held by a company and intended to be exercised) and the expected life of the improvement. The useful life, depreciation method and residual value of an asset are reviewed at least each year-end and any changes are accounted for prospectively as a change in accounting estimate. Depreciation of an asset ceases at the earlier of the date that the asset is classified as held for sale and the date that the asset is derecognized. i. Intangible assets: Separately acquired intangible assets are measured on initial recognition at cost including directly attributable costs. Intangible assets acquired in a business combination are measured at fair value at the acquisition date. Expenditures relating to internally generated intangible assets, excluding capitalized development costs, are recognized in profit or loss when incurred. Intangible assets with a finite useful life are amortized over their useful life and reviewed for impairment whenever there is an indication that the asset may be impaired. The amortization period and the amortization method for an intangible asset are reviewed at least at each year end. j. Impairment of non-financial assets: The Company evaluates the need to record an impairment of non-financial assets whenever events or changes in circumstances indicate that the carrying amount is not recoverable. If the carrying amount of non-financial assets exceeds their recoverable amount, the assets are reduced to their recoverable amount. The recoverable amount is the higher of fair value less costs of sale and value in use. In measuring value in use, the expected future cash flows are discounted using a pre-tax discount rate that reflects the risks specific to the asset. The recoverable amount of an asset that does not generate independent cash flows is determined for the cash-generating unit to which the asset belongs. Impairment losses are recognized in profit or loss. k. Financial instruments: 1. Financial assets: Financial assets are measured upon initial recognition at fair value plus transaction costs that are directly attributable to the acquisition of the financial assets, except for financial assets measured at fair value through profit or loss in respect of which transaction costs are recorded in profit or loss. The Company classifies and measures debt instruments in the financial statements based on the following criteria: - The Company’s business model for managing financial assets; and - The contractual cash flow terms of the financial asset. a) Debt instruments are measured at amortized cost when: The Company’s business model is to hold the financial assets in order to collect their contractual cash flows, and the contractual terms of the financial assets give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding. After initial recognition, the instruments in this category are measured according to their terms at amortized cost using the effective interest rate method, less any provision for impairment. On the date of initial recognition, the Company may irrevocably designate a debt instrument as measured at fair value through profit or loss if doing so eliminates or significantly reduces a measurement or recognition inconsistency, such as when a related financial liability is also measured at fair value through profit or loss. b) Debt instruments are measured at fair value through profit or loss when: A financial asset which is a debt instrument does not meet the criteria for measurement at amortized cost or at fair value through other comprehensive income. After initial recognition, the financial asset is measured at fair value and gains or losses from fair value adjustments are recognized in profit or loss. c) Equity instruments and other financial assets held for trading: Investments in equity instruments do not meet the above criteria and accordingly are measured at fair value through profit or loss. Other financial assets held for trading such as derivatives, including embedded derivatives separated from the host contract, are measured at fair value through profit or loss unless they are designated as effective hedging instruments. Dividends from investments in equity instruments are recognized in profit or loss when the right to receive the dividends is established. 2. Derecognition of financial assets: A financial asset is derecognized only when: - The contractual rights to the cash flows from the financial asset have expired; - The Company has transferred substantially all the risks and rewards deriving from the contractual rights to receive cash flows from the financial asset or has neither transferred nor retained substantially all the risks and rewards of the asset, but has transferred control of the asset; or - The Company has retained its contractual rights to receive cash flows from the financial asset but has assumed a contractual obligation to pay the cash flows in full without material delay to a third party. 3. Financial liabilities: a) Financial liabilities measured at amortized cost: Financial liabilities are initially recognized at fair value less transaction costs that are directly attributable to the issue of the financial liability. After initial recognition, the Company measures all financial liabilities at amortized cost using the effective interest rate method, except for financial liabilities at fair value through profit or loss such as derivatives. b) Financial liabilities measured at fair value through profit or loss: At initial recognition, the Company measures financial liabilities that are not measured at amortized cost at fair value. Transaction costs are recognized in profit or loss. After initial recognition, changes in fair value are recognized in profit or loss. 4. Derecognition of financial liabilities: A financial liability is derecognized only when it is extinguished, that is when the obligation specified in the contract is discharged or cancelled or expires. A financial liability is extinguished when the debtor discharges the liability by paying in cash, other financial assets, goods or services, or is legally released from the liability. 5. Offsetting financial instruments: Financial assets and financial liabilities are offset and the net amount is presented in the statement of financial position if there is a legally enforceable right to set off the recognized amounts and there is an intention either to settle on a net basis or to realize the asset and settle the liability simultaneously. The right of set-off must be legally enforceable not only during the ordinary course of business of the parties to the contract but also in the event of bankruptcy or insolvency of one of the parties. In order for the right of set-off to be currently available, it must not be contingent on a future event, there may not be periods during which the right is not available, or there may not be any events that will cause the right to expire. 6. Compound financial instruments: Convertible debentures which contain both an equity/derivative component and a liability component are separated into two components. This separation is performed by first determining the liability component based on the fair value of an equivalent non-convertible liability. The value of the conversion component is determined to be the residual amount. Directly attributable transaction costs are apportioned between the equity component and the liability component based on the allocation of proceeds to the equity and liability components. 7. Issue of a unit of securities: The issue of a unit of securities involves the allocation of the proceeds received (before issue expenses) to the securities issued in the unit based on the following order: financial derivatives and other financial instruments measured at fair value in each period. Then fair value is determined for financial liabilities that are measured at amortized cost. The proceeds allocated to equity instruments are determined to be the residual amount. Issue costs are allocated to each component pro rata to the amounts determined for each component in the unit. l. Research and development expenditures: Research expenditures are recognized in profit or loss when incurred. The conditions enabling capitalization of development costs as an asset have not yet been met and, therefore, all development expenditures are recognized in profit or loss when incurred. m. Finance income and expenses: Finance income and expenses comprise interest income on amounts invested and exchange rate gains and losses. Interest income is recognized as it accrues using the effective interest method. Finance income and expenses derive also from changes in the fair value of financial liabilities measured at fair value through profit or loss. Borrowing costs are recognized in profit or loss using the effective interest method. n. Fair value measurement: Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value measurement is based on the assumption that the transaction will take place in the asset’s or the liability’s principal market, or in the absence of a principal market, in the most advantageous market. The fair value of an asset or a liability is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants act in their economic best interest. Fair value measurement of a non-financial asset takes into account a market participant’s ability to generate economic benefits by using the asset in its highest and best use or by selling it to another market participant that would use the asset in its highest and best use. The Company uses valuation techniques that are appropriate in the circumstances and for which sufficient data are available to measure fair value, maximizing the use of relevant observable inputs and minimizing the use of unobservable inputs. All assets and liabilities measured at fair value or for which fair value is disclosed are categorized into levels within the fair value hierarchy based on the lowest level input that is significant to the entire fair value measurement: Level 1 - Quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 - Inputs other than quoted prices included within Level 1 that are observable directly or indirectly. Level 3 - Inputs that are not based on observable market data (valuation techniques which use inputs that are not based on observable market data). o. Taxes on income: Current or deferred taxes are recognized in profit or loss, except to the extent that they relate to items which are recognized in other comprehensive income or equity. 1. Current taxes: A current tax liability is measured using the tax rates and tax laws that have been enacted or substantively enacted by the reporting date as well as adjustments required in connection with the tax liability in respect of previous years. 2. Deferred taxes: Deferred taxes are computed in respect of temporary differences between the carrying amounts in the financial statements and the amounts attributed for tax purposes. Deferred taxes are measured at the tax rate that is expected to apply when the asset is realized, or the liability is settled, based on tax laws that have been enacted or substantively enacted by the reporting date. Deferred tax assets are reviewed at each reporting date and reduced to the extent that it is not probable that they will be utilized. Deductible carryforward losses and temporary differences for which deferred tax assets had not been recognized are reviewed at each reporting date and a respective deferred tax asset is recognized to the extent that their utilization is probable. Taxes that would apply in the event of the disposal of investments in investees have not been taken into account in computing deferred taxes, as long as the disposal of the investments in investees is not probable in the foreseeable future. Also, deferred taxes that would apply in the event of distribution of earnings by investees as dividends have not been taken into account in computing deferred taxes, since the distribution of dividends does not involve an additional tax liability or since it is the Company’s policy not to initiate distribution of dividends from a subsidiary that would trigger an additional tax liability. Taxes on income that relate to distributions of an equity instrument and to transaction costs of an equity transaction are accounted for pursuant to IAS 12, “ Income Taxes Deferred taxes are offset if there is a legally enforceable right to offset a current tax asset against a current tax liability and the deferred taxes relate to the same taxpayer and the same taxation authority. p. Share/ADS-based payment transactions: The Company’s employees and other service providers may receive remuneration in the form of share/ADS-based payments (“Equity-settled transactions”). Equity-settled transactions: The cost of equity-settled transactions with employees is measured at the fair value of the equity instruments granted at grant date. The fair value is determined using an acceptable option pricing model (“OPM”). As for service providers, the cost of the transactions is measured at the fair value of the goods or services received as consideration for equity instruments granted. The cost of equity-settled transactions is recognized in profit or loss together with a corresponding increase in equity during the period in which the performance and/or service conditions are to be satisfied ending on the date on which the relevant employees become entitled to the award (the “Vesting Period”). The cumulative expense recognized for equity-settled transactions at the end of each reporting period until the vesting date reflects the extent to which the Vesting Period has expired and the Company’s best estimate of the number of equity instruments that will ultimately vest. No expense is recognized for awards that do not ultimately vest, except for awards where vesting is conditional upon a market condition, which are treated as vesting irrespective of whether the market condition is satisfied, provided that all other vesting conditions (service and/or performance) are satisfied. If the Company modifies the conditions on which equity-instruments were granted, an additional expense is recognized for any modification that increases the total fair value of the share-based payment arrangement or is otherwise beneficial to the employee/other service provider at the modification date. If a grant of an equity instrument is cancelled, it is accounted for as if it had vested on the cancellation date and any expense not yet recognized for the grant is recognized immediately. However, if a new grant replaces the cancelled grant and is identified as a replacement grant on the grant date, the cancelled and new grants are accounted for as a modification of the original grant, as described above. q. Earnings (loss) per share/ADS: Earnings (loss) per share or per ADS are calculated by dividing the income (loss) attributable to equity holders of the Company by the weighted number of ordinary shares or ADSs outstanding during the period. Basic loss per ordinary share or ADS includes only ordinary shares or ADSs that were outstanding during the period. Potential ordinary shares or ADSs are included in the computation of diluted loss per ordinary share or per ADS when their conversion increases loss per ordinary share or ADS from continuing operations. r. Employee benefit liabilities: The Company has several employee-benefit plans: 1. Short-term employee benefits: Short-term employee benefits are benefits that are expected to be settled wholly before twelve months after the end of the annual reporting period in which the employees render the related services. These benefits include salaries, paid annual leave, paid sick leave, recreation and social security contributions and are recognized as expenses as the services are rendered. A liability in respect of a cash bonus or a profit-sharing plan is recognized when the Company has a legal or constructive obligation to make such payment as a result of past service rendered by an employee and a reliable estimate of the amount can be made. 2. Post-employment benefits: The plans are normally financed by contributions to insurance companies and classified as defined contribution plans or as defined benefit plans. The Company has defined contribution plans to its employees according to the specific laws per country. s. Provisions: A provision in accordance with IAS 37, “ Provisions, Contingent Liabilities and Contingent Assets Following are the types of provisions included in the financial statements: Legal claims: A provision for claims is recognized when the Company has a present legal or constructive obligation as a result of a past event, it is more likely than not that an outflow of resources embodying economic benefits will be required by the Company to settle the obligation and a reliable estimate can be made of the amount of the obligation. t. Leases: The Company elected to apply the provisions of IFRS 16, “ Leases The accounting policy for leases applied effective from January 1, 2019, is as follows: The Company accounts for a contract as a lease when the contract terms convey the right to control the use of an identified asset for a period of time in exchange for consideration. 1. The Company as a lessee: For leases in which the Company is the lessee, the Company recognizes on the commencement date of the lease a right-of-use asset and a lease liability, excluding leases whose term is up to 12 months and leases for which the underlying asset is of low value. For these excluded leases, the Company has elected to recognize lease payments as an expense in profit or loss on a straight-line basis over the lease term (see Note 9). In measuring the lease liability, the Company has elected to apply the practical expedient in IFRS 16 and separates the lease components from the non-lease components (such as management and maintenance services, etc.) included in a single contract. On the commencement date, the lease liability includes all unpaid lease payments discounted at the interest rate implicit in the lease, if that rate can be readily determined, or otherwise using the Company’s incremental borrowing rate. After the commencement date, the Company measures the lease liability using the effective interest rate method. On the commencement date, the right-of-use asset is recognized in an amount equal to the lease liability plus lease payments already made on or before the commencement date and initial direct costs incurred. The right-of-use asset is measured applying the cost model and depreciated over the shorter of its useful life and the lease term. The Company tests for impairment of the right-of-use asset whenever there are indications of impairment pursuant to the provisions of IAS 36, “ Impairment of Assets 2. Lease extension and termination options: A non-cancelable lease term includes both the periods covered by an option to extend the lease when it is reasonably certain that the extension option will be exercised, and the periods covered by a lease termination option when it is reasonably certain that the termination option will not be exercised. In the event of any change in the expected exercise of the lease extension option or in the expected non-exercise of the lease termination option, the Company remeasures the lease liability based on the revised lease term using a revised discount rate as of the date of the change in expectations. The total change is recognized in the carrying amount of the right-of-use asset until it is reduced to zero, and any further reductions are recognized in profit or loss. 3. Lease modifications: If a lease modification does not reduce the scope of the lease and does not result in a separate lease, the Company remeasures the lease liability based on the modified lease terms using a revised discount rate as of the modification date and records the change in the lease liability as an adjustment to the right-of-use asset. If a lease modification reduces the scope of the lease, the Company recognizes a gain or loss arising from the partial or full reduction of the carrying amount of the right-of-use asset and the lease liability. The Company subsequently remeasures the carrying amount of the lease liability according to the revised lease terms, at the revised discount rate as of the modification date and records the change in the lease liability as an adjustment to the right-of-use asset. The accounting policy for leases applied until December 31, 2018, is as follows: The criteria for classifying leases as finance or operating leases depend on the substance of the agreements and are made at the inception of the lease in accordance with the following principles as set out in IAS 17, “ Leases The Company as lessee: Operating leases: Leases in which substantially all the risks and rewards of ownership of the leased asset are not transferred to the Company are classified as operating leases. Lease payments are recognized as an expense in profit or loss on a straight-line basis over the lease term.

Significant Accounting Judgment

Significant Accounting Judgments, Estimates and Assumptions Used in the Preparation of the Financial Statements	12 Months Ended
	Dec. 31, 2020
Significant Accounting Judgments, Estimates and Assumptions Used in the Preparation of the Financial Statements [Abstract]
SIGNIFICANT ACCOUNTING JUDGMENTS, ESTIMATES AND ASSUMPTIONS USED IN THE PREPARATION OF THE FINANCIAL STATEMENTS	NOTE 3:- SIGNIFICANT ACCOUNTING JUDGMENTS, ESTIMATES AND ASSUMPTIONS USED IN THE PREPARATION OF THE FINANCIAL STATEMENTS In the process of applying the significant accounting policies, the Company has made the following judgments which have the most significant effect on the amounts recognized in the financial statements: a. Judgments: - Discount rate for a lease liability: When a company in the Group is unable to readily determine the discount rate implicit in a lease in order to measure the lease liability, such company uses an incremental borrowing rate. That rate represents the rate of interest that the Company would have to pay to borrow over a similar term and with similar security, the funds necessary to obtain an asset of similar value to the right-of-use asset in a similar economic environment. When there are no financing transactions that can serve as a basis, said company determines the incremental borrowing rate based on its credit risk, the lease term and other economic variables deriving from the lease contract’s conditions and restrictions. - Effective control: The Company assesses whether it controls a company in which it holds less than the majority of the voting rights by, among others, reference to the size of its holding of voting rights relative to the size and dispersion of holdings of the other vote holders including voting patterns at previous shareholders’ meetings. - Determining the fair value of share-based payment transactions: The fair value of share-based payment transactions is determined upon initial recognition by an acceptable OPM. The inputs to the model include share price, exercise price and assumptions regarding expected volatility, expected life of share option, risk-free interest and expected dividend yield. b. Estimates and assumptions: The preparation of the financial statements requires management to make estimates and assumptions that have an effect on the application of the accounting policies and on the reported amounts of assets, liabilities, revenues and expenses. Changes in accounting estimates are reported in the period of the change in estimate. The key assumptions made in the financial statements concerning uncertainties at the reporting date and the critical estimates computed by the Company that may result in a material adjustment to the carrying amounts of assets and liabilities within the next financial year are discussed below. - Legal claims: In estimating the likelihood of outcome of legal claims filed or threatened to commence against the Company and/or its Subsidiaries and/or affiliates, the Company relies on its management’s best knowledge and estimations and where applicable, on the opinion of their legal counsels. These estimates are based, among others, on management’s familiarity of and proximity to the circumstances, and also on the legal counsels’ best professional judgment, taking into account the stage of proceedings and legal precedents in respect of the different issues. Since the outcome of the claims might be determined in courts and/or other quasi-judicial tribunals, the results could differ from these estimates. - Lease extension and/or termination options: In evaluating whether it is reasonably certain that a company of the Group will exercise an option to extend a lease or not exercise an option to terminate a lease, the Company considers all relevant facts and circumstances that create an economic incentive for the Company to exercise the option to extend or not exercise the option to terminate such as: significant amounts invested in leasehold improvements, the significance of the underlying asset to the Company’s operation and whether it is a specialized asset, the company’s past experience with similar leases, etc. After the commencement date, the Company reassesses the term of the lease upon the occurrence of a significant event or a significant change in circumstances that affects whether the company is reasonably certain to exercise an option or not exercise an option previously included in the determination of the lease term, such as significant leasehold improvements that had not been anticipated on the lease commencement date, sublease of the underlying asset for a period that exceeds the end of the previously determined lease period, etc. - Fair value of financial instruments: When the fair values of financial assets and financial liabilities recorded in the statement of financial position cannot be derived from active markets, their fair value is determined using a variety of valuation techniques that include the use of valuation models. The inputs to these models are taken from observable markets where possible, but where this is not feasible, estimation is required in establishing fair values. The models are tested for validity by calibrating to prices from any observable current market transactions in the same instrument when available.

Discontinued Operations

Discontinued Operations	12 Months Ended
	Dec. 31, 2020
Disclosure of discontinued operations [text block] [Abstract]
DISCONTINUED OPERATIONS	NOTE 4:- DISCONTINUED OPERATIONS: Deconsolidation of THR: On July 31, 2018, the Company entered into an agreement for convertible equity (the “Convertible Equity Agreement”) with THR, then an unaffiliated third party. Since July 31, 2018, THR was engaged in operating pain treatment clinics, mainly in Tennessee, to treat an assortment of different pains, including, acute pain, spine pain, chronic headaches, cancer pain, oral/maxillofacial pain, neuropathic pain and rheumatologic/myofascial pain. Under the Convertible Equity Agreement, the Company loaned an aggregate amount of $1,625 (the “THR Loan”) to THR. The maturity date of the THR Loan, which accrued interest at a rate of 9% per annum, was to occur upon demand of the Company and under certain conditions. On October 3, 2018, following the occurrence of the conditions required under the Convertible Equity Agreement for conversion of the THR Loan, the Company converted the entire THR Loan and as a result held 82.36% of THR’s equity, and accordingly obtained control over THR. Until December 31, 2018, no further changes were made to THR’s equity. On December 31, 2018, due to significant losses incurred by THR, as well as its failure to maintain required licenses to operate its facilities, the Company decided to fully impair the goodwill and additional intangible assets which have arisen from THR’s acquisition in the amount of $160 and $273, respectively. On March 26, 2019, following the financial deterioration of THR, THR’s board of directors resolved that THR will commence a liquidation process of its assets, a process which ended on June 27, 2019, with the confirmation of THR’s Dissolution by submitting all documents required by law. As of April 2019, THR had no employees and all business operations were discontinued. Accordingly, the Company presented all profit or loss results relevant to THR as loss from discontinued operations, net. Also, as of June 27, 2019, THR had no assets or liabilities and recorded an income in the amount of $616 (THR recorded a loss of $2,400 during the period since consolidation on October 3, 2018, up until December 31, 2018). In addition, the Company concluded that following THR’s Dissolution on June 27, 2019, and given that THR had no operations since April 2019 and there was no longer a board of directors, that it lost its control over THR and accordingly deconsolidated THR on June 27, 2019 from the Group’s consolidated financial statements. Since the Acquisition Date and until April 8, 2019, the Company loaned to THR an additional total amount of $822, which loans included an interest rate of 9% per annum, in order to allow THR to maintain its ongoing operations. The loss, following the fact that the above-mentioned loans will not be repaid, was attributed to the equity holders of the Company (discontinued operations). The loss following the fact that the above-mentioned loans will not be repaid was attributed to the equity holders of the Company (discontinued operations). Below is data of the net cash flows provided by (used in) the discontinued operations: Year ended December 31, 2020 2019 Operating activities $ - $ (1,024 ) Investing activities - 724 Financing activities $ - $ -

Cash

Cash	12 Months Ended
	Dec. 31, 2020
Cash [Abstract]
CASH	NOTE 5:- CASH December 31, 2020 2019 Cash for immediate withdrawal - in USD $ 1,878 $ 760 Cash for immediate withdrawal - in NIS 68 110 $ 1,946 $ 870

Other Accounts Receivable

Other Accounts Receivable	12 Months Ended
	Dec. 31, 2020
Other Accounts Receivable [Abstract]
OTHER ACCOUNTS RECEIVABLE	NOTE 6:- OTHER ACCOUNTS RECEIVABLE December 31, 2020 2019 Government authorities $ 103 $ 41 Other receivables 183 23 Prepaid expenses 308 11 $ 594 $ 75

Convertible Loan

Convertible Loan	12 Months Ended
	Dec. 31, 2020
Convertible Loan [Abstract]
CONVERTIBLE LOAN	NOTE 7:- CONVERTIBLE LOAN On April 17, 2018, the Company entered into a convertible loan agreement with Cure Pharmaceutical Holding Corp. (the “Convertible Loan Agreement” and “Cure”, respectively), a U.S.-based company. Under the Convertible Loan Agreement, the Company lent Cure an amount of $500 (the “Cure Loan”). The maturity date of the Cure Loan, together with an interest at a rate of 9% per annum, was set as April 30, 2019 (the “Maturity Date”). In addition, according to the Convertible Loan Agreement, the Company had the option to instruct Cure, prior to the Maturity Date, to repay the Cure Loan amount together with all interest accrued thereon, in lieu of the conversion (described below), in which case Cure will effect such repayment on the Maturity Date. Furthermore, the Convertible Loan Agreement set forth several options by which the Cure Loan could be converted. On December 31, 2018, the Company instructed Cure to repay the Cure Loan (with the 9% accrued interest) on the Maturity Date and as a result the Cure Loan was fully repaid by Cure, including interest in the amount of $46, on April 30, 2019. Accordingly, the Convertible Loan Agreement was terminated with no further effect.

Investment in Associates and In

Investment in Associates and Investments in Investees	12 Months Ended
	Dec. 31, 2020
Investment in Associates and Investments in Investees [Abstract]
INVESTMENT IN ASSOCIATES AND INVESTMENTS IN INVESTEES	NOTE 8:- INVESTMENT IN ASSOCIATES AND INVESTMENTS IN INVESTEES a. Investment in Lara: On June 15, 2014, a definitive investment agreement was signed between the Company and Lara, an Israeli company that operates in the field of medical cannabis, which determined, among others, that the Company will invest in Lara up to a total of $1,500, subject to the fulfillment of several prerequisites (the “Investment Agreement”). Under the Investment Agreement, the Company undertook to transfer to Lara an initial investment amount of $800 in exchange for the issuance of 48% of Lara’s issued and outstanding share capital (approximately 27% on a fully diluted basis). In May 2016, following various claims that the parties held against each other, the Company and Lara signed a settlement and termination agreement (the “Settlement Agreement”). Under the Settlement Agreement, the parties agreed that the Company will continue to hold approximately 27% of Lara’s share capital, and that it will be released from making the remaining payments under the Investment Agreement and all other terms of the Investment Agreement will have no further binding effect. Pursuant to the Settlement Agreement, the Company’s representative on Lara’s board of directors resigned. The Company also forfeited its right to appoint a director. Accordingly, the Company no longer has significant influence over Lara. As of December 31, 2019, the balance of the investment in Lara was $0. b. Sale of Orimmune Bio Ltd. and the Termination of the Hadasit License Agreement: On June 22, 2016, the Company entered into a share transfer agreement (the “Transfer Agreement”) with its then wholly owned subsidiary, Orimmune Bio Ltd. (“Orimmune”) and Karma Link Ltd. (the “Buyer”), whereby the Company would sell its interests in Orimmune to the Buyer, and also use its best efforts to transfer to and assign Orimmune its rights in the Anti-CD3 technology (which was in-licensed by the Company during 2010 from Hadasit Medical Research Services & Development Ltd. (“Hadasit”), and certain internally developed assets and technology relating thereto) (the “License”), and also assist in obtaining all the necessary approvals for such technology transfer (including from Hadasit, but without undertaking a commitment for the technology transfer, which required Hadasit’s pre-approval). In consideration of the forgoing, it was agreed that the Company would be entitled to a predetermined rate (which is a low double-digit number) of all receipts which the Buyer will receive from Orimmune or from third parties in connection with the sale of shares and/or assets of Orimmune, up to an aggregate of approximately $10. For each receipt in excess of said aggregate amount, the Company will be entitled to a lower rate determined therefrom (also a low double-digit number) (such rates shall be regarded herein after as the “Predetermined Rates”). In August 2016, the Transfer Agreement was closed; and the Company sold and transferred its holding in Orimmune to the Buyer and as a result of the loss of control, the Company recorded a capital gain in the amount of $34. During May 2017, the parties agreed to amend the Transfer Agreement (the “First Amendment”), under which the parties acknowledged that the process of assigning the License and transferring the License, as contemplated in the Transfer Agreement, had yet to mature into an agreement with Hadasit (by no fault of the Company). As a result, the Company agreed to bear certain expenses related to the License incurred by the Buyer prior to the date of the First Amendment and additional such expenses expected during the six-month period thereafter (and which otherwise would have had supposedly been borne by the Buyer), and which aggregated in the total to approximately $75. The parties to the Transfer Agreement further agreed that in the event that the parties were unable to successfully assign the License within said six-month period, the Company would be deemed to have satisfied its obligation to use reasonable commercial efforts, in accordance with the Transfer Agreement. In consideration of the foregoing, the parties agreed to increase the percentages of the Predetermined Rate of all receipts that the Buyer may receive from Orimmune or from third parties in connection with the sale by the Buyer of Orimmune’s shares and/or assets. After not succeeding in assigning the License to the Buyer, on March 29, 2018, the Company and Hadasit signed a mutual termination agreement of the License (the “Termination Agreement”), according to which, among others, the License (including the consulting agreements associated with said License) was terminated as of that date, except for certain matters as prescribed thereunder. In connection with the Termination Agreement, the Company paid Hadasit the outstanding amount owed and/or to be owed to Hadasit under the License until terminated (which was later set as an amount of $104), and certain intellectual property (“IP”) rights were assigned back to Hadasit and other IP rights had to be jointly registered, all pending the Israeli Innovation Authority’s (“IIA”) approval, which was obtained in June 2018. On December 13, 2018, an additional amendment to the Transfer Agreement was signed (the “Second Amendment”) between the parties, under which it was acknowledged that the Company’s termination of the License agreement with Hadasit was due to Orimmune’s (and the Buyer’s) decision not to enter into a subsequent license agreement with Hadasit. Under that Second Amendment, it was agreed that Orimmune (and the Buyer) will be assigned certain rights in IP related to the licensed technology owned by the Company subject to certain conditions precedent which were still not met as of December 31, 2020. As of the Approval Date, the Company received the approval of the IIA to complete the assignment and the Company is acting to complete the transaction. c. Coeruleus - Joint Venture Transaction On May 15, 2020, the Company entered into a series of transactions (together, the “Joint Venture Transaction”), including a definitive share transfer agreement with Capital Point Ltd. (“Capital Point”), an Israeli holding company traded on the TASE, and Evero, pursuant to which Capital Point sold to Evero 5,952,469 ordinary shares, NIS 0.01 par value each, of Coeruleus Ltd. (the “Purchased Coeruleus Shares” and “Coeruleus,” respectively), an Israeli company and a subsidiary of Capital Point (owns approximately 46%), engaged in, among others, developing innovative medications based on the active generic substance flumazenil, including a sublingual spray to reduce the side effects of hypnotic sleep medication, and a sublingual spray to improve function and quality of life in patients with hepatic encephalopathy. The Purchased Coeruleus Shares represented approximately 35% of the issued and outstanding share capital of Coeruleus. In consideration thereof, Evero issued and sold to Capital Point 176,470 ordinary shares, NIS 1.00 par value each, constituting 15% of the issued and outstanding share capital of Evero, which was valued at $351, based on apportionment of the fair market value of the Company as reflected on Nasdaq as of May 15, 2020. Following the transaction, Capital Point held approximately 11% of Coeruleus’ issued and outstanding share capital. The transaction costs of $51 were also capitalized as part of the investment in associate. As part of the Joint Venture Transaction, the Company transferred to Evero its SCI-110 sleep technology, to be fully owned by Evero, under the terms and conditions of an asset purchase agreement. In addition, the Company issued to Capital Point a warrant (the “Capital Point Warrant”) to purchase $340 of ADSs of the Company. Pursuant to the terms of the Capital Point Warrant, the exercise price per ADS is equal to the closing price of the Company’s ADSs on the trading day on which the notice of exercise was actually received by the Company, and shall be paid by transferring to the Company a duly executed share transfer deed for 9,577 ordinary shares of Evero. The Capital Point Warrant is exercisable for twelve months starting from the twelve-month anniversary of the issuance date, which was May 15, 2020. On November 29, 2020, the shareholders of Coeruleus approved an investment from its shareholders of approximately $30. The Company did not participate in this investment in Coeruleus and therefore, as of the completion of such financing, the Company held less than 1% of the issued and outstanding shares of Coeruleus.

Leases

Leases	12 Months Ended
	Dec. 31, 2020
Leases [Abstract]
LEASES	NOTE 9:- LEASES On July 10, 2017, effective August 1, 2017, the Company entered into a three-year lease agreement with a third party (the “Period”) for an area of approximately 205 square meters for the Company’s offices in the district of Tel Aviv (the City of Givatayim), Israel. The yearly lease fee according was set at approximately $65, linked to the NIS. The lease expired on July 31, 2020. The Company did not exercise its option to extend the Period until July 31, 2023. On September 1, 2020, the Company entered into a one-year lease agreement (“the 2020 Lease”) with a third party for an area of approximately 100 square meters for the Company’s offices in the district of Tel Aviv, Israel. The Company has an option to extend for an additional five-year term. The Company deemed this option as not-reasonably certain to be renewed. The yearly lease fee was set at approximately $44, linked to the NIS. Since the 2020 Lease has a duration of no more than 12 months, the 2020 Lease was not recognized on the statement of financial position.

Property and Equipment, Net

Property and Equipment, Net	12 Months Ended
	Dec. 31, 2020
Property and Equipment, Net [Abstract]
PROPERTY AND EQUIPMENT, NET	NOTE 10:- PROPERTY AND EQUIPMENT, NET Assets owned and used by the Company Right-of- Computers Lab equipment Office furniture and equipment Leasehold improvements Motor vehicles Leasehold office Total Cost: Balance at January 1, 2020 $ 20 $ 12 $ 23 $ 29 $ - $ 193 $ 277 Effect of non-application of IFRS 16 - - - - - (193 ) (193 ) Purchases - - - - - - - Disposals - - - (29 ) - - (29 ) Balance at December 31, 2020 20 12 23 - - - 55 Accumulated depreciation: Balance at January 1, 2020 15 12 11 7 57 102 Effect of non-application of IFRS 16 - - - - - (57 ) (57 ) Depreciation 4 - 2 2 - 7 Disposals - - - (9 ) - - (9 ) Balance at December 31, 2020 19 12 13 - - - 44 Depreciated cost at December 31, 2020 1 - 10 - - - 11 Balance at January 1, 2019 66 2,004 134 29 8 - 2,241 Effect of non-application of IFRS 16 - - - - - 193 193 Purchases 1 - - - - - 1 Disposals (47 ) (1,992 ) (111 ) - (8 ) - (2,158 ) Balance at December 31, 2019 20 12 23 29 - 193 227 Accumulated depreciation: Balance at January 1, 2019 16 97 16 4 1 - 134 Effect of non-application of IFRS 16 - - - - - 57 57 Depreciation 10 102 53 3 2 - 122 Disposals (11 ) (187 ) (10 ) - (3 ) - (211 ) Balance at December 31, 2019 15 12 11 7 - 57 102 Depreciated cost at December 31, 2019 $ 5 $ - $ 12 $ 22 $ - $ 136 $ 175 Depreciation expenses for the years ended December 31, 2020 and 2019, amounted to $7 and $67, respectively.

Trade Payables

Trade Payables	12 Months Ended
	Dec. 31, 2020
Trade Payables [Abstract]
TRADE PAYABLES	NOTE 11:- TRADE PAYABLES December 31, 2020 2019 Accrued expenses $ 279 $ 525 Open debts 277 339 $ 556 $ 864

Other Accounts Payable

Other Accounts Payable	12 Months Ended
	Dec. 31, 2020
Other Accounts Payable [Abstract]
OTHER ACCOUNTS PAYABLE	NOTE 12:- OTHER ACCOUNTS PAYABLE December 31, 2020 2019 Employees and payroll accruals $ 20 $ 68 Accrued vacation 14 40 $ 34 $ 108

Financial Instruments

Financial Instruments	12 Months Ended
	Dec. 31, 2020
Financial Instruments [Abstract]
FINANCIAL INSTRUMENTS	NOTE 13:- FINANCIAL INSTRUMENTS a. Classification of financial assets and financial liabilities: The financial assets and financial liabilities in the consolidated statements of financial position are classified by groups of financial instruments pursuant to IFRS 9, “ Financial Instruments December 31, 2020 2019 Financial assets: Cash and restricted deposits $ 1,956 $ 904 1,956 904 Financial liabilities: Current financial liabilities carried at amortized cost 188 972 Credit from others, including short-term lease liability - 67 Warrants liability 353 7 Lease liability - 94 $ 541 $ 1,140 b. Convertible Debentures: On November 23, 2018 (the “Issuance Date”), the Company entered into a securities purchase agreement (the “Securities Purchase Agreement”) and a registration rights agreement with YA II PN Ltd. (“Yorkville”), a fund managed by Yorkville Advisors Global L.P., for the sale in a private placement of up to $2,500 in principal amount of unsecured convertible debentures (the “Convertible Debentures”). Interest on the Convertible Debentures will accrue at a rate of 5% per annum and can be repaid in cash with an addition of an 10% redemption premium upon the maturity date of the Convertible Debentures, being 12 months from the issuance of each Convertible Debenture. The first tranche of $1,500 of the Convertible Debentures was issued on November 26, 2018. In addition, $78 was deducted due to issue expenses, and Yorkville received 131 ADSs of the Company in return to additional commitment fees (valued at $75). Also, an additional fee of $10 was deducted from the $1,500 due to payments to Yorkville’s legal counsels. Two additional tranches of $500 each of the Convertible Debentures shall be purchased by Yorkville conditional on the passage of time and/or certain triggering events as disclosed in the Securities Purchase Agreement. If the Company will not comply with the triggering events mentioned, the Company will be deemed to be in default pursuant to the terms, and inter alia, the interest on the Convertible Debentures will accrue up to a rate of 15% per annum. The Company shall pay Yorkville additional commitment fees upon issuance of each such tranche, to be paid at the Company’s option in cash or ADSs of the Company. From and after the date of issuance of the Convertible Debentures, the outstanding principal, together with accrued and unpaid interest, will be convertible, at the option of Yorkville, into the Company’s ADSs at the lower of $7.00 or 95% of the lowest daily volume-weighted average price (“VWAP”) during the five consecutive trading days immediately preceding the conversion date. On March 28, 2019, as part of a financing round (see Note 17e.1), Yorkville agreed to invest $250 by converting $250 of the principal outstanding amount ($1,500) under the Convertible Debentures. As a result of the conversion, the Company issued to Yorkville 1,020 ADSs. In addition, as part of the financing round above-mentioned, the Company issued to Yorkville a warrant to purchase up to 765 ADSs. Since July 8, 2019, up until September 13, 2019, Yorkville converted the rest of the principal outstanding amount under the Convertible Debentures, by converting $100 on July 8, 2019; $450 on July 23, 2019; $375 on August 30, 2019; and $325 on September 13, 2019 - refer to Note 17f for more information. Valuation process and techniques: The Company’s management considers the appropriateness of the valuation methods and inputs and may request that alternative valuation methods are applied to support the valuation arising from the method chosen. The valuation of the Convertible Debentures was set in accordance with IFRS 9 and IAS 32, “ Financial Instruments: Presentation According to IFRS 9 and IAS 32, the allocation is based on the following hierarchy: - Derivative and other financial instrument measured at fair value through its contractual life. - Financial liabilities and other complex instruments which are not recognized at fair value. - Equity instruments. IFRS 9 and IAS 32 also determine that a derivative which may be settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity’s own equity instruments, will be defined as a financial liability, measured and presented at fair value each period. Accordingly, and as mentioned in the Securities Purchase Agreement, in the event of conversion, the number of shares to be issued is unknown (not fixed). Therefore, according to the definition mentioned above, the conversion component is classified as a financial liability that will be measured at fair value, through profit or loss, as of the Issuance Date and on any following financial reporting date (accordingly, issue expenses related to the derivative will be recorded through profit or loss). The remainder of the consideration will be attributed to the debt component and no consideration will be left to attribute to the equity instrument (issuance of 131 ADSs mentioned above). The valuation of the conversion component of Convertible Debentures was set at fair value, as required in IFRS 9, and in accordance with IFRS 13, “ Fair value measurement General Overview of Valuation Approaches used in the Valuation: Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Economic methodology: The convertible component was calculated using the Monte Carlo Simulation Model, an OPM which takes into account the parameters as disclosed below for each period valuated, in which a valuation was performed at (i) the Issuance Date, (ii) each reporting date and (iii) prior to each conversion. Hereinafter are the ranges of the parameters used: The price of the ADS as of the valuation date ($) 164.5-238 The exercise price of the option (*) ($) 490 The expected volatility of the price of the ADS (%) 79.2-116.1 The risk-free interest rate for the option contractual term (%) 1.97-2.52 The expected dividends over the option’s expected term (%) 0 Maturity date November 23, 2019 (*) The lower of $490.00 or 95% of the lowest daily VWAP during the five consecutive trading days immediately preceding the conversion date. Hereinafter is the reconciliation of the fair value measurements (the conversion component of the Convertible Debentures) that are categorized within Level 3 of the fair value hierarchy in financial instruments: Balance at January 1, 2018 $ - Issuance at November 23, 2018 745 Net change in fair value of the conversion component designated at fair value through profit or loss (468 ) Balance at December 31, 2018 277 Net change in fair value of the conversion component designated at fair value through profit or loss (82 ) Conversion of the proportional part out of the conversion component (195 ) Balance at December 31, 2019 $ - c. Bridge Loan On January 15, 2020, the Company entered into a bridge loan agreement (the “Bridge Loan”) with a third party, in which the third party lent to the Company $50 (the “Bridge Loan Amount”). On April 17, 2020, the Bridge Loan Amount was fully repaid by the Company, including interest in the amount of $2. Accordingly, the Bridge Loan was terminated with no further effect. d. Line of Credit On September 8, 2020, the Company entered into a certain credit agreement (the “Credit Facility”), with M.R.M. Merchavit Holdings and Management Ltd. (the “Lender”), whereby the Lender agreed to extend a line of credit to the Company in the aggregate amount of $200, or the Credit Amount. According to the terms of the Credit Facility, $100 of the Credit Amount (the “Loan Amount”), was immediately drawn on the date of the Credit Facility, and the remaining $100 was available be drawn on an as-needed basis. The Loan Amount was due upon the earlier of one year from September 8, 2020 or at such time that the Company raised $1,500. The Lender was entitled to a transaction and interest fee of $5 (plus VAT) that was offset from the Credit Facility for the immediately drawn $100 and 5% from any additional withdrawal amount from the Credit Facility. On November 24, 2020, the Loan Amount was fully repaid by the Company. e. Dekel On March 19, 2020, the Company entered into a securities purchase agreement with Dekel Pharmaceutical Ltd. (“Dekel”) pursuant to which Dekel agreed to invest in the Company through a private placement transaction (the “Private Placement”). At the time of the Private Placement, Dekel was considered as a related party to the Company; however, it is no longer a related party to the Company. In connection with the Private Placement, Dekel received convertible promissory notes (the “Notes”), with an aggregate original principal amount of approximately $350, at an aggregate purchase price of $315 to be paid in several tranches spread across a twelve-month period. In addition, the Company issued a warrant to purchase up to 4,490 ADSs of the Company (the “Private Placement Warrant”) and 571 ADSs. The initial tranche of the Private Placement was for a principal amount of $220 at a purchase price of $198. The Notes are unsecured, have a maturity date of March 23, 2021, bear interest at a rate of 12% per annum, and may be converted, at the election of the holder, into ADSs at an initial conversion price of $24.50 per ADS (the “Fixed Conversion Price”), subject to adjustments. After the six-month anniversary of the issuance of the Notes, the conversion price shall be equal to the lower of the Fixed Conversion Price or 70% of the lowest trading price of the ADSs as reported on Nasdaq or any exchange upon which the ADSs or ordinary shares of the Company are traded at such time, for the 20 prior trading days including the day upon which a notice of conversion is received by the Company or its transfer agent. The Private Placement Warrant is exercisable at any time on or after the actual closing date and on or prior to the close of business on the five-year anniversary of the date of issuance, at an initial exercise price of $24.5 per ADS, subject to adjustment. On November 8, 2020, the Notes was terminated and the initial tranche was fully repaid by the Company. General Overview of Valuation Approaches used in the Valuation: Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Economic methodology: The warrants’ fair value was calculated using the Black–Scholes OPM, which takes into account the parameters as disclosed below for each period valuated, in which a valuation was performed at (i) the issuance date, and (ii) each reporting date with the following assumptions: December 31, March 23, Dividend yield (%) 0 0 Expected volatility (%) 132 122.01 Risk-free interest rate (%) 0.38 0.38 Underlying Share Price ($) 3.625 30.1 Exercise price ($) 24.5 24.5 Warrants fair value ($) 2.22 25.2 f. Financial risk factors: The Company’s activities expose it to various financial risks such as market risks (foreign currency risk and interest risk), credit risk and liquidity risk. The Company’s comprehensive risk management plan focuses on activities that reduce to a minimum any possible adverse effects on the Company’s financial performance. Risk management is performed by management in accordance with the policies approved by the Company’s board of directors (the “Board”). The Board establishes written principles for the overall risk management activities as well as specific policies with respect to certain exposures to risks such as exchange rate risk, credit risk and the investments of surplus funds. 1. Market risks: Foreign currency risk: The Company is exposed to exchange rate risk resulting from the exposure to different currencies, mainly from transactions in NIS. Exchange rate risk arises from recognized liabilities that are denominated in a foreign currency other than the functional currency. 2. Credit risks: All cash and restricted deposits related to the Company are held in two banks in Israel which are considered financially solid. 3. Liquidity risk: The Company monitors the risk of a shortage of funds on a regular basis and acts to raise funds to satisfy its liabilities. As of December 31, 2020, the Company expects to settle all of its financial liabilities in less than one year. The carrying amounts of cash and restricted deposits, and all other financial assets and liabilities approximate their fair value. Refer to Note 1c for more information.

Employee Benefit Liabilities

Employee Benefit Liabilities	12 Months Ended
	Dec. 31, 2020
Employee Benefit Liabilities [Abstract]
EMPLOYEE BENEFIT LIABILITIES	NOTE 14:- EMPLOYEE BENEFIT LIABILITIES Employee benefits consist of short-term benefits and post-employment benefits. Post-employment benefits: According to the labor laws and the Israeli Severance Pay Law, 1963 (the “Severance Pay Law”), the Company is required to pay compensation to an employee upon dismissal or retirement or to make current contributions in defined contribution plans pursuant to Section 14 of the Severance Pay Law, as specified below. The Company’s liability is accounted for as a post-employment benefit. The computation of the Company’s employee benefit liability is made in accordance with a valid employment contract based on the employee’s salary and employment term which establish the entitlement to receive the compensation. The post-employment benefits are normally financed by contributions classified as defined benefit plans or as defined contribution plans as detailed below. Defined contribution plans: Section 14 of the Severance Pay Law applies to a substantial part of the compensation payments, pursuant to which the fixed contributions paid by the Company into pension funds and/or policies of insurance companies release the Company from any additional liability to employees for whom said contributions were made. These contributions and contributions for compensation represent defined contribution plans. Year ended 2020 2019 2018 Expenses in respect of defined contribution plans $ 52 $ 50 $ 65

Taxes on Income

Taxes on Income	12 Months Ended
	Dec. 31, 2020
Taxes on Income [Abstract]
TAXES ON INCOME	NOTE 15:- TAXES ON INCOME a. Tax rates applicable to the Company: The Israeli statutory corporate tax rate and real capital gains tax rate were 23% in 2020, 2019, and 2018. b. Tax assessments: The assessments of the Company are deemed final through the 2014 tax year. In addition, as of December 31, 2020, through the date of THR’s Dissolution, it met all reporting obligations. c. Carryforward tax losses and other temporary differences: The Company has accumulated tax losses since its inception. As of December 31, 2020, the Company’s net carryforward tax losses are estimated to grow to approximately $43,000 ($39,000 as of December 31, 2019).

Contingent Liabilities, Commitm

Contingent Liabilities, Commitments, Claims and Liens	12 Months Ended
	Dec. 31, 2020
Contingent Liabilities Commitments And Liens [Abstract]
CONTINGENT LIABILITIES, COMMITMENTS, CLAIMS AND LIENS	NOTE 16:- CONTINGENT LIABILITIES, COMMITMENTS, CLAIMS AND LIENS a. New License Agreement with Ramot at Tel Aviv University Ltd.: In February 2016, the Company entered into an exclusive, irrevocable, worldwide research and license agreement with Ramot for a patent application relating to methods for treatment of cognitive decline with low doses of THC (the “Ramot License Agreement”). The Company undertook to pay certain expenses in relation to certain IP covered under the Ramot License Agreement, and to fund further research in an amount of approximately $62. In addition, certain milestones fees and payments were set under the Ramot License Agreement. On March 13, 2019, further to discussions between the Company and Ramot, the Company notified Ramot of its intent to terminate the Ramot License Agreement, and it was effectively terminated on May 13, 2019, without any additional costs borne by the Company. At the date of termination of the Ramot License Agreement and as of the Approval Date, the Company does not believe that said termination will have a material effect on the Company’s operations and business. b. License Agreement with Dekel Pharmaceuticals Ltd.: In May 2015, the Company entered into an exclusive, irrevocable, worldwide license agreement with Dekel for certain technology and one granted U.S. patent related to compositions and methods for treating inflammatory disorders (the “Dekel License Agreement”). The Dekel License Agreement became effective in August 2015. Pursuant to the Dekel License Agreement, the Company is obligated to pay Dekel fees based on specific milestones and royalties upon commercialization. The milestone payments include: (i) $25 upon the successful completion of preclinical trials (which milestone was met in November 2016; this milestone was paid in cash in March 2017); (ii) $75 upon the successful completion of a Phase I/IIa trial; and (iii) $75 upon the earlier of generating net revenues of at least $200 from the commercialization of the technology or the approval of the U.S. Food and Drug Administration or the European Medicines Agency, of a drug based on the licensed assets. In each case, and subject to the Company’s discretion, the respective milestone payments are payable in cash or equity based on a price per ordinary share of NIS 0.5. The royalty payments are 8% for commercialization and 35% pursuant to a sub-license of the licensed assets. The patent expiration dates of any patents maturing from this application would likely be 2029. On July 14, 2019, an amendment to the Dekel License Agreement was signed (the “Amendment”), which encompasses the Company and Dekel’s original intention to exclude certain consumer packaged goods (meaning, inter alia, food, beverage, cosmetics, pet products and hemp based products, which are sources of nutrients or other substances which may have a nutritional effect) from the scope of the licensed products and the field of activity of the Company described in the Dekel License Agreement. The parties agreed to amend the Dekel License Agreement to reflect the foregoing clarification, as well as certain additional less material matters as discussed in the Amendment. The Amendment also prescribes for a specific development plan under the Dekel License Agreement requiring the Company to invest in the licensed technology (as defined under the License Agreement) formulation development and maintenance a total annual investment to be capped at $350. The Amendment also included a non-compete and non-solicitation obligation by Dekel and Dr. Ascher Shmulewitz, the Company’s former Executive Chairman of the Board and former interim Chief Executive Officer, towards the Company’s field of activity. On November 13, 2019, an additional milestone under the Dekel License Agreement, in the amount of $75, was reached upon the successful completion of a Phase IIa clinical trial. The Company paid the milestone amount on April 13, 2020. c. License Agreement with Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (“Yissum”): On July 29, 2018, the Company entered into an exclusive, worldwide, sublicensable, royalty-bearing license with Yissum for a license to make commercial use of the licensed technology, in order to develop, obtain regulatory approvals, manufacture, market, distribute or sell products, all within the field and the territory only, as determined in the agreement (the “Yissum License Agreement”). According to the Yissum License Agreement, the Company shall pay Yissum royalties at the rates of future net sales, subject to the royalty reductions as described in the Yissum License Agreement. The Company is also obligated to pay sublicense fees out of the sublicense consideration. All right, title and interest in and to the Yissum License Agreement shall vest solely in Yissum, and the Company shall hold and make use of the rights granted. All rights in the development results shall be solely owned by the Company, except to the extent that an employee of Yissum, including the researcher, is considered an inventor of a patentable invention arising from the development results, in which case such invention and all patent applications and/or patents claiming such invention shall be owned jointly by the Company and Yissum, as appropriate, and Yissum’s share in such joint patents shall be automatically included in the Yissum License Agreement. d. Investigator-initiated study contract with Hannover Medical School: On April 11, 2017, the Company entered into an investigator-initiated study contract with Hannover Medical School (“MHH”) to conduct during 2018 a phase IIb clinical trial titled “A Randomized, Double-Blind, Placebo controlled study to Evaluate the Safety, Tolerability and Efficacy of Up to Twice Daily Oral SCI-110 in Treating Adults with Tourette Syndrome” in treating approximately 20 Tourette syndrome subjects aged 18 to 65. Upon the execution of the agreement the Company paid the first installment in the amount of $122 out of a total estimated amount of approximately $776. Due to regulatory and strategic reasons, the Company decided to change the study design from investigator-initiated to an industry sponsored trial. During October 2017, a discussion was carried out between the Company and MHH and the latter was informed about this change and a termination letter stating the above was sent to MHH on November 19, 2017. MHH has acknowledged that part of the first instalment that was paid by the Company, in accordance with the initial agreement, will be used to set-off amounts owed under a new agreement or will be paid back to the Company. On August 13, 2018, the Company entered into an agreement with MHH to conduct a clinical investigation and laboratory services for a randomized, double-blind, placebo-controlled proof of concept study to evaluate the safety, tolerability and efficacy of daily oral SCI-110 in treating adults with Tourette syndrome in an estimated amount of $835. e . All litigations and claims that were attributed to THR were settled or terminated prior to or following THR’s Dissolution (see Note 4). As of December 31, 2020, there are no pending litigations or claims against the Company, which according to the best knowledge and estimations of the Company’s management, require a provision as such. f . During October 2019, the Company received a letter of demand from a former service provider (the “Service Provider”) outlining an alleged debt of approximately $85. The Company rejects all such claims which are not supported by the facts and denies any outstanding debt owed to the service provider by the Company and under the circumstances, the Company’s management estimates that no provision is required as of December 31, 2020. In addition, as of the Approval Date, no formal claim was filed by the Service Provider on this matter. g . On July 23, 2020, the Company submitted to the Tel Aviv-Jaffa District Court (the “Court”) a petition pursuant to the Israeli Insolvency and Economic Rehabilitation Law, 2018, to commence proceedings for the economic rehabilitation of the Company (the “Petition”). In the Petition submitted to the Court, the Company stated that it is insolvent (as determined by the cash flow test) and unable to pay its debts to the Company’s creditors. On August 6, 2020, L.I.A. Pure Capital Ltd. (“Pure Capital”) filed with the Court a demand, requesting an order to have the results of the Company’s annual general meeting held on August 4, 2020 declared invalid, mainly due to the Company’s reliance on discretionary voting of the depositary bank for the Company’s ADSs. The Court asked for the Company and directors’ response by no later than August 13, 2020, which was subsequently extended. On August 11, 2020, Pure Capital proposed to deposit $1,500 with the Company’s temporary trustee nominated by the Court to cover and pay all of the Company’s debts, without derogating from any other creditor’s rights towards the Company (the “Pure Capital Proposal”). The Pure Capital Proposal was made subject to the replacement of the Company’s Board as of the date of the Pure Capital Proposal (the “Prior Board”) with Pure Capital’s designated nominees that were voted upon at the adjourned annual general meeting of the Company’s shareholders on August 4, 2020 (as discussed below). The Court issued an order on August 14, 2020 (the “Order”), approving the Pure Capital Proposal and settlement agreement submitted to the Court by the parties thereto. In accordance with the terms of the Order and following the deposit by Pure Capital, the Prior Board was replaced with: Itschak Shrem (chairman), Amity Weiss (also appointed to act as the Company’s Chief Executive Officer), Moshe Revach, Lior Amit, Lior Vider and Liat Sidi. Following the issuance of the Order, a related case that was filed by Pure Capital with the Court was withdrawn as well. On December 15, 2020, Mr. Lior Amit tendered his resignation from the Board.

Equity

Equity	12 Months Ended
	Dec. 31, 2020
Equity [Abstract]
EQUITY	NOTE 17:- EQUITY a. Composition of share capital: December 31, December 31, Authorized Issued and outstanding Authorized Issued and outstanding Number of shares Ordinary shares 1,800,000,000 145,148,593 15 ,000,000 11,439,401 Description of ADSs: The Bank of New York Mellon, as depositary, registers and delivers the Company’s ADSs. Each ADS represents one hundred and forty (140) ordinary shares. Each ADS will also represent any other securities, cash or other property which may be held by the depositary. Reverse Share Split On September 17, 2020, the Company convened a special general meeting of its shareholders, whereby the shareholders approved, inter alia, (i) an increase to the Company’s share capital from 500,000,000 ordinary shares to 750,000,000 ordinary shares; and (ii) a reverse split of the Company’s share capital up to a ratio of 20:1 (the “Reverse Split”). On October 16, 2020, the Company convened a special general meeting of its shareholders, whereby the shareholders approved an increase to the Company’s share capital from 750,000,000 ordinary shares to 1,800,000,000 ordinary shares. On October 1, 2020, the Company’s Board resolved that the final ratio for the Reverse Split will be 20:1, which went effective on October 16, 2020. Concurrently with the Reverse Split, a change to the ratio of its ADSs to its ordinary shares was effective pursuant to which each ADS representing 40 ordinary shares changed to each ADS representing 140 ordinary shares. This resulted in a reverse split on the Company’s American Depositary Receipt program. Consequently, all share numbers, share prices, and exercise prices have been retroactively adjusted in these consolidated financial statements for all periods presented. b. Changes in share capital: Issued and outstanding share capital: Number of Balance at January 1, 2020 11,439,401 Issue of share capital - 2020 Financing Rounds (Note 17e) 125,375,916 Conversion of Warrants (Note 17e) 8,333,276 Balance at December 31, 2020 145,148,593 c. Rights attached to shares: Voting rights at the shareholders meeting, right to dividends, rights upon liquidation of the Company and right to nominate the directors in the Company. d. Capital management in the Company: The Company’s capital management objectives are to preserve the Company’s ability to ensure business continuity thereby creating a return for the shareholders, investors and other interested parties. The Company is not under any minimal equity requirements nor is it required to attain a certain level of capital return. e. Financing Rounds: 1. March 2019 Financing Round: On March 28, 2019, the Company entered into a definitive securities purchase agreement (the “Purchase Agreement”) with institutional investors to purchase (i) 9,184 of the Company’s ADSs, representing 1,285,760 ordinary shares, at a purchase price of $245 per ADS, in a registered direct offering (the “Registered Direct Offering”); and (ii) warrants to purchase up to 6,888 ADSs, representing 964,320 ordinary shares, with an initial exercise price of $245 per ADS (the “Warrants”), in a concurrent private placement (the “March 2019 Financing Round” and, together with the Registered Direct Offering, the “Offerings”). The March 2019 Financing Round included an investment from Yorkville that was made by converting $250 of the principal outstanding amount under the Convertible Debentures (see Note 13b). The total gross proceeds to the Company from the Offerings was $2,000, not including the conversion above mentioned by Yorkville and net of issue expenses in the total amount of $356, out of which $248 were attributed to the Registered Direct Offering and the additional $108 were attributed to the Warrants. The closing of the sale of the ADSs and Warrants occurred on April 1, 2019. The ADSs issued under the Registered Direct Offering were issued pursuant to a prospectus supplement dated as of March 28, 2019, which was filed with the SEC in connection with a takedown from the Company’s shelf registration statement on Form F-3, which became effective on July 20, 2018. The Warrants which were issued in the March 2019 Financing Round, along with the ADSs issuable upon their exercise, were offered pursuant to Section 4(a)(2) under the Securities Act of 1933, as amended, and Regulation D promulgated thereunder and may not be offered or sold in the United States absent registration with the SEC or an applicable exemption from such registration requirements. The Warrants were immediately exercisable upon issuance for a period of three years, at an exercise price of $245 per share. In addition, the Warrants have a cashless exercise mechanism (the “Cashless Mechanism”), which provides that if at any time after the six months anniversary of their issuance there is no effective registration statement, or no current prospectus available for the resale of the ADSs underlying the Warrants by the holder, then these Warrants may also be exercised, in whole or in part, at such time by means of a “cashless exercise”. On August 22, 2019, the Company registered the resale of 6,566 ADSs underlying the Warrants. As of the Approval Date, none of the Warrants were exercised. Valuation process and techniques: The Company’s management considers the appropriateness of the valuation methods and inputs and may request that alternative valuation methods are applied to support the valuation arising from the method chosen. The allocation of the consideration received from the bundle of securities is based on the method of the remainder of consideration, when there is a hierarchy regarding the financial instruments measured at fair value and the financial instruments recognized as the remainder of consideration. Valuation of Warrants: Since the Warrants have a Cashless Mechanism, there is no certainty, at the time of signing the Purchase Agreement, regarding the number of ADSs that will be issued, meaning the Warrants are defined as a financial liability, and therefore, will be calculated and presented in fair value, upon the Issuance Date and at each reporting date that follows, unless the ADSs underlying the Warrants will be registered for resale and as a result the Cashless Mechanism will be cancelled and accordingly the Company will have to classify the Warrants as equity. Valuation of ADSs: The Company’s ADSs are an equity instrument which will set as the residual value of the proceeds, less the fair value of the Warrants. General Overview of Valuation Approaches used in the Valuation: Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Economic methodology: The Warrants fair value was calculated using the Black-Scholes OPM with the following assumptions: March 28, August 22, December 31, Dividend yield (%) 0 0 0 Expected volatility (%) 70.12 84.97 189 Risk-free interest rate (%) 2.18 1.48 0.17 Expected life of Warrants (years) 3 2.58 1.24 Warrants fair value ($) 1.41 1.01 0.37 As above-mentioned, on August 22, 2019 (the “Registration Date”), the Company registered for resale 459,640 ADSs underlying the Warrants, and as a result of the registration, the Warrants were classified as equity at the fair value as of the Registration Date which was $464. Reconciliation of the fair value measurements that are categorized within Level 3 of the fair value hierarchy in financial instruments: Balance of liability due to Warrants at January 1, 2020 $ 7 Reclassification of warrants to liability 464 Net change in fair value of the Warrant designated at fair value through profit or loss (468 ) Balance of liability due to Warrants at December 31, 2020 $ 3 2. December 2019 Financing Round: On December 3, 2019, the Company entered into definitive securities purchase agreements with institutional investors to purchase an aggregate 14,286 of the Company’s ADSs, representing 2,000,040 ordinary shares, at a purchase price of $87.5 per ADS in a registered direct offering (the “December Registered Direct Offering”). The proceeds to the Company from the December Registered Direct Offering were $1,029, net of issue expenses in the total amount of $221. 3. April 2020 Financing Round On April 1, 2020, the Company entered into a definitive securities purchase agreement (the “April 2020 Purchase Agreement”) with institutional investors to purchase of 59,524 units, each consisting of (i) one pre-funded warrant to purchase one ADS and (ii) one Series B warrant to purchase one ADS, at a purchase price of $20.993 per unit. The Series B warrants have an exercise price of $30.10 per ADS, are exercisable upon issuance and expire five years from the date of issuance. The offering resulted in gross proceeds to the Company of approximately $1,250. The closing of the sale of the securities took place on April 3, 2020. After the closing of the April 2020 Purchase Agreement and until the Approval Date, all pre-funded warrants were exercised. In addition, 59,524 of the Series B warrants were exercised pursuant to a cashless exercise mechanism as described in the April 2020 Purchase Agreement for no further consideration to the Company. As of the Approval Date, all Series B warrants were exercised. The Series B warrants are classified as a financial liability that will be measured at fair value, through profit or loss, as of the issuance date and on any following financial reporting date (accordingly, issue expenses related to the Series B warrants will be recorded through profit or loss). No consideration will be left to attribute to the pre-funded warrants, which is an equity instrument. The valuation of the conversion component of the Series B warrants was set at fair value, as required in IFRS 9, and in accordance with IFRS 13, and was categorized as Level 3 by the Company. Hereinafter is the reconciliation of the fair value measurements that are categorized within Level 3 of the fair value hierarchy in financial instruments: Balance at January 1, 2020 $ - Issuance at April 3, 2020 $ 1,250 Net change in fair value of the Series B warrants designated at fair value through profit or loss 172 Conversion part of Series B warrants (1,422 ) Balance at December 31, 2020 $ - 4. November 2020 Financing Round On November 20, 2020, the Company completed an offering for gross proceeds of $4,200 by way of the issuance of an aggregate of 835,447 units, each consisting of (i) one ADS and (ii) two warrants to purchase one ADS each, at a purchase price of $5.02 per unit (“November 2020 Warrants”). The November 2020 Warrants have an exercise price of $5.02 per ADS, will be exercisable upon issuance and will expire five years from the date of issuance. The November 2020 Warrants are classified as issued warrants in the Company’s equity. f. Additional issuance of ordinary shares/ADSs: Further to the matter discussed in Note 13b, since July 8, 2019, up until September 13, 2019, Yorkville converted the rest of the principal outstanding amount under the Convertible Debentures, by converting $100 on July 8, 2019; $450 on July 23, 2019; $375 on August 30, 2019; and $325 on September 13, 2019, in which following the conversions, the Company issued to Yorkville 8,151 ADSs, representing 1,141,140 ordinary shares. The total consideration, including the conversion of $250 as part of the 2019 March Financing Round, was $1,507.

Share-Based Payment Transaction

Share-Based Payment Transactions	12 Months Ended
	Dec. 31, 2020
Share-based Payment Transactions [Abstract]
SHARE-BASED PAYMENT TRANSACTIONS	NOTE 18:- SHARE-BASED PAYMENT TRANSACTIONS a. The cost of share-based payment recognized in the financial statements: The expenses due to share-based compensation for the years ended December 31, 2020, 2019 and 2018, recognized in the financial statements in respect of the share option plan of the Company is shown in the following table, detailed by departments: Year ended December 31, 2020 2019 2018 Research and development expenses $ 69 $ 165 $ 109 General and administrative expenses 22 388 495 $ 91 $ 553 $ 604 1. The 2005 and 2015 ESOP of the Company: During 2005, the Board adopted the 2005 Employees Share Option Plan (the “2005 ESOP”). Ten years later the Board adopted a new plan - the 2015 Employees Share Option Plan (the “2015 ESOP”). Under both the 2005 ESOP and 2015 ESOP, the Company may grant its employees and other service providers options to purchase the Company’s ordinary shares (“Share Options”). On November 13, 2019, the Board reserved an additional number of 950,000 Share Options for the purposes of the 2015 ESOP, bringing the amount of Share Options reserved under the 2015 ESOP to 2,200,000, out of which a total of 1,410,000 were still available for grant as of December 31, 2020. Each ADS option (“ADS Options”) granted under the 2015 ESOP represents one hundred and forty (140) Share Options and vice versa. 2. On March 12, 2019, the Board approved and granted 1,171 ADS Options (equal to 164,000 Share Options) under the 2015 ESOP to a new consultant of the Company. The exercise price was set at $420.00 per ADS Option. The fair value for ADS Options granted to the consultant was estimated using the Black-Scholes OPM with the following parameters: Dividend yield (%) 0 Expected volatility (%) 76 Risk-free interest rate (%) 2.61 Expected life of share options (years) 10 The fair value of the ADSs options was set at $224 per ADS Option. 3. On October 10, 2019 (the “Grant Date”), the Board approved the grant of 10,129 ADS Options (equal to 1,418,060 Share Options) under the 2015 ESOP to directors, officers and employees, some of which required the approval of the general meeting of the Company’s shareholders (the “General Meeting”), which occurred on January 15, 2020. Following the resignation of some directors and employees on December 31, 2019, 2,143 ADS Options (equal to 300,020 Share Options) were not granted. Out of the 7,986 ADS Options that were granted, 1,395 ADS Options didn’t require the General Meeting’s approval. The date of commencement for all ADS Options granted, the date on which the vesting started, was the Grant Date. The exercise price was set at $210.00 per ADS Option. According to IFRS 2, “ Share-based Payment Based on the above-mentioned, hereinafter are the parameters used in order to estimate the fair value of the ADS Options using the Black-Scholes OPM: October 10, December 31, Underlying ADS price 154 78.12 Dividend yield (%) 0 0 Expected volatility (%) 70 73 Risk-free interest rate (%) 1.67 1.91 Expected life of share options (years) 10 9.78 The fair value of the ADSs options approved on October 10, 2019 by the Board, and on January 15, 2020 at the General Meeting (valuated as of December 31, 2019) was set at $114.1 and $51.1, per ADS Option, respectively. b. Movement during the year: 1. The following table lists the number of Share Options or ADS Options, the weighted average exercise prices of Share Options or ADS Options and changes in directors (and former directors), officers, employees and consultants Share Options or ADS Options during the years ended on December 31, 2020 and 2019: Number of Weighted Number of Weighted 2020 USD USD Share/ADS Options outstanding at the beginning of the year 2,101,402 $ 2.41 15,010 $ 337.40 Share/ADS Options granted during the year - - - - Share/ADS Options forfeited during the year (1,311,402 ) 2.50 (18,734 ) 175.00 Share/ADS Options expired during the year - - - - Share/ADS Options outstanding at the end of the year 790,000 2.41 11,285 168.70 Share/ADS Options exercisable at the end of the year 498,660 3.41 7,120 168.70 2019: Share/ADS Options outstanding at the beginning of the year 890,652 $ 3.00 6,361 $ 432.60 Share/ADS Options granted during the year 1,282,000 1.60 9,157 236.60 Share/ADS Options forfeited during the year (18,750 ) 2.80 (134 ) 392.00 Share/ADS Options expired during the year (52,500 ) 3.80 (375 ) 532.00 Share/ADS Options outstanding at the end of the year 2,101,402 2.41 15,010 337.40 Share/ADS Options exercisable at the end of the year 828,484 3.41 5,918 467.60 2. The weighted average fair value of Share Options and ADS Options granted during 2019 was 0.6 and 84, respectively. No Share/ADS Options were granted during 2020. 3. The weighted average remaining contractual life of the Share/ADS Options outstanding was 5 years and 7.47 years as of December 31, 2020 and 2019, respectively. 4. The range of exercise prices of Share Options outstanding at the end of the year was $1.50 - $6.43 (inclusive)_as of December 31, 2020, and $1.50 - $6.20 (inclusive) as of December 31, 2019. The range of exercise prices of ADS Options outstanding at the end of the year was $210 - $900.20 (inclusive) as of December 31, 2020, and $210 - $868 (inclusive) as of December 31, 2019.

Additional Information to the I

Additional Information to the Items of Profit or Loss	12 Months Ended
	Dec. 31, 2020
Additional Information To Items Of Profit Or Loss [Abstract]
ADDITIONAL INFORMATION TO THE ITEMS OF PROFIT OR LOSS	NOTE 19:- ADDITIONAL INFORMATION TO THE ITEMS OF PROFIT OR LOSS Year ended 2020 2019 2018 a. Research and development expenses Wages and related expenses $ 322 $ 435 $ 667 Share-based payment 69 165 109 Regulatory, professional and other expenses 119 437 595 Research and preclinical studies 139 277 593 Clinical studies - 240 692 Chemistry and formulations - 85 54 649 1,639 2,710 b. General and administrative expenses Wages and related expenses 237 382 761 Share-based payment 22 388 495 Professional and directors’ fees 1,283 1,065 1,154 Business development expenses 58 387 1,323 Regulatory expenses 98 112 72 Office maintenance, rent and other expenses 182 72 198 Investor relations and business expenses 22 63 368 1,902 2,469 4,371 c. Other expenses Impairment of goodwill - - 160 Impairment of investment in associate 742 - - 742 - 160 d. Finance income Net change in fair value of financial liabilities designated at fair value through profit or loss (630 ) (292 ) (468 ) Exchange rate differences, net - (2 ) (303 ) Finance income from the convertible loan - (11 ) (35 ) Intercompany finance income - - (22 ) (630 ) (305 ) (828 ) e. Finance expenses Finance expenses due to the convertible debentures - 536 112 Issue expenses related to convertible component and warrants 835 108 - Exchange rate differences, net 12 - - Interest expense in respect of leases 7 19 - Finance expenses from interest and commissions 18 13 9 $ 872 $ 676 $ 121

Loss Per Share_Ads

Loss Per Share/Ads	12 Months Ended
	Dec. 31, 2020
Loss Per Share Or Ads [Abstract]
LOSS PER SHARE/ADS	NOTE 20:- LOSS PER SHARE/ADS a. Details of the number of shares and loss used in the computation of loss per share: Year ended December 31, 2020 2019 2018 Amounts used in the computation of basic and diluted loss Weighted Loss Weighted Loss Weighted Loss In thousands USD In thousands USD In thousands USD Continuing operations: Basic loss per share 36,143 (3,482 ) 8,580 $ (4,479 ) 6,996 $ (6,534 ) Effect of potential dilutive ordinary shares 964 (468 ) - - 972 (395 ) Diluted loss per share 37,107 (3,950 ) 8,580 (4,479 ) 7,968 (6,929 ) Discontinued operations: Basic and Diluted loss per share - - 8,580 (315 ) 6,996 (1,989 ) Effect of potential dilutive ordinary shares - - - - 972 - Diluted loss per share - $ - 8,580 $ (315 ) 7,968 $ (1,989 ) b. The computation of diluted loss per share or ADS did not include the following convertible securities since their inclusion would decrease the loss per share (anti-dilutive effect): 1. Ordinary share or ADS Options to employees, officers, directors and consultants; and 2. Non-marketable warrants to investors.

Operating Segments

Operating Segments	12 Months Ended
	Dec. 31, 2020
Operating Segments [Abstract]
OPERATING SEGMENTS	NOTE 21:- OPERATING SEGMENTS The Company applies the principles of IFRS 8, “ Operating Segments

Transactions and Balances with

Transactions and Balances with Related Parties	12 Months Ended
	Dec. 31, 2020
Transactions and Balances With Related Parties [Abstract]
TRANSACTIONS AND BALANCES WITH RELATED PARTIES	NOTE 22:- TRANSACTIONS AND BALANCES WITH RELATED PARTIES a. Balances with related parties: December 31, December 31, Key Other Key Other Current liabilities $ 59 $ - $ 208 $ - b. Transactions with related parties (not including amounts described in Note 22c): Year ended 2020 2019 2018 Research and development expenses $ - $ 75 $ 75 General and administrative expenses $ - $ - $ 769 c. Benefits to key management personnel (including directors): Year ended 2020 2019 2018 Short-term benefits $ 746 $ 948 $ 1,379 Cost of share-based payment $ 91 $ 275 $ 520

Events After The Reporting Date

Events After The Reporting Date	12 Months Ended
	Dec. 31, 2020
Events After Reporting Date [Abstract]
EVENTS AFTER THE REPORTING DATE	NOTE 23:- EVENTS AFTER THE REPORTING DATE a. On January 7, 2021, the general meeting of the Company’s shareholders approved the election of Mr. Amnon Ben Shay and Mr. Alon Dayan to serve as external directors of the Company, for a three-year term commencing as of the date of such meeting. b. On March 2, 2021, the general meeting of the Company’s shareholders approved amendments to the Company’s Amended and Restated Articles of Association to eliminate the par value of the Company’s ordinary shares and to increase the Company’s share capital to 3,600,000,000 ordinary shares. c. On March 4, 2021, the Company completed a private offering with several accredited and institutional investors for gross proceeds of $8,150, providing for the issuance of an aggregate of 1,152,628 units, as follows: (a) 916,316 units at a price of $7.07 per unit, consisting of (i) one ADS of the Company, and (ii) a Series A Warrant to purchase an equal number of units purchased (the “2021 Series A Warrant”) and a Series B Warrant (the “2021 Series B Warrant”) to purchase half the number of units (the “Ordinary Warrants”), and (b) 236,312 pre-funded units at a price of $7.069 per unit, consisting of (i) one pre-funded warrant to purchase one ADS and (ii) one 2021 Series A Warrant and one 2021 Series B Warrant. The Series A Warrant have an exercise price of $7.07 per ADS and the Series B Warrants have an exercise price of $10.60 per ADS. Both the Series A Warrants and the Series B Warrants are exercisable six months from the date of issuance and will expire five years from the date of issuance. The offering resulted in gross proceeds to the Company of approximately $8,150.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	12 Months Ended
	Dec. 31, 2020
Accounting Policies [Abstract]
Basis of presentation of the financial statements	a. Basis of presentation of the financial statements: These financial statements have been prepared in accordance with IFRS, as issued by the IASB. The Company’s financial statements have been prepared on a cost basis, unless otherwise indicated. The Company has elected to present the profit or loss items using the function of expense method. The financial statements are presented in USD and all values are rounded to the nearest thousand (‘000), except when otherwise indicated.
The operating cycle	b. The operating cycle: The operating cycle of the Company is one year.
Consolidated financial statements	c. Consolidated financial statements: The consolidated financial statements comprise the financial statements of companies that are controlled by the Company (Subsidiaries). Control of a company is achieved when the Company is exposed, or has rights, to variable returns from its involvement with the investee and has the ability to affect those returns through its power over the investee. Potential voting rights are considered when assessing whether an entity has control over the other entity. The consolidation of the financial statements commences on the date on which control is obtained and ends when such control ceases. The financial statements of the Company and of the Subsidiaries are prepared as of the same dates and periods. The consolidated financial statements are prepared using uniform accounting policies by all companies in the Group. Significant intra-Group balances and transactions and gains or losses resulting from intra-Group transactions are eliminated in full in the consolidated financial statements. Non-controlling interests in subsidiaries represent the equity in subsidiaries not attributable, directly or indirectly, to a parent. Non-controlling interests are presented in equity separately from the equity attributable to the equity holders of the Company. Profit or loss and components of other comprehensive income are attributed to the Company and to non-controlling interests. Losses are attributed to non-controlling interests even if they result in a negative balance of non-controlling interests in the consolidated statement of financial position.
Discontinued operations	d. Discontinued operations: A discontinued operation is a component of the Company that either has been disposed of or is classified as held for sale. The operating results relating to the discontinued operation are presented separately in profit or loss, net of the tax effect.
Functional currency and foreign currency	e. Functional currency and foreign currency: 1. Functional currency and presentation currency: Effective on October 1, 2018, due to changes in certain economic facts and circumstances, the functional currency of the Company was changed from the New Israeli Shekel (“NIS”) to USD. Thus, the functional and reporting currency of the Company is the USD. In determining the appropriate functional currency that should be used, the Company followed the guidance in IAS 21, “ The Effects of Changes in Foreign Exchange Rates All resulting translation differences until October 1, 2018, following the fact that the reporting currency was different than the functional currency, were recognized as a separate component of other comprehensive income (loss) in equity “foreign currency translation reserve.” The functional currency of THR up until THR’s Dissolution, was also USD. 2. Transactions, assets and liabilities in foreign currency: Transactions denominated in foreign currency (other than the functional currency) are recorded on initial recognition at the exchange rate at the date of the transaction. After initial recognition, monetary assets and liabilities denominated in foreign currency are translated at each reporting date into the functional currency at the exchange rate at that date. Non-monetary assets and liabilities denominated in foreign currency and measured at fair value are retranslated into the functional currency using the exchange rate prevailing at the date when the fair value was determined. Non-monetary assets and liabilities measured at cost are translated at the exchange rate at the date of the transaction.
Business combinations and goodwill	f. Business combinations and goodwill: Business combinations are accounted for by applying the acquisition method. The cost of the acquisition is measured at the fair value of the consideration transferred on the acquisition date with the addition of non-controlling interests in the acquiree. In each business combination, the Company chooses whether to measure the non-controlling interests in the acquiree based on their fair value on the acquisition date or at their proportionate share in the fair value of the acquiree’s net identifiable assets. Direct acquisition costs are carried to the statement of profit or loss as incurred. Goodwill is initially measured at cost which represents the excess of the acquisition consideration and the amount of non-controlling interests over the net identifiable assets acquired and liabilities assumed. If the resulting amount is negative, the acquirer recognizes the resulting gain on the acquisition date.
Restricted deposits	g. Restricted deposits: A restricted deposit is cash invested in a short-term deposit (between three months and one year) or in a long-term deposit (with a maturity of more than one year from the date of investment). Restricted deposits are designated to secure the Company’s office facilities lease agreements and its credit cards.
Property and equipment, net	h. Property and equipment, net: Property and equipment are measured at cost, including directly attributable costs, less accumulated depreciation, accumulated impairment losses and any related investment grants and excluding day-to-day servicing expenses. Depreciation is calculated on a straight-line basis over the useful life of the assets at annual rates as follows: % Mainly % Lab equipment 6-50 33 Computers 33-50 33 Office furniture and equipment 20-33 25 Motor vehicles 55 - Leasehold improvements see below - Leasehold improvements are depreciated on a straight-line basis over the shorter of the lease term (including the extension option held by a company and intended to be exercised) and the expected life of the improvement. The useful life, depreciation method and residual value of an asset are reviewed at least each year-end and any changes are accounted for prospectively as a change in accounting estimate. Depreciation of an asset ceases at the earlier of the date that the asset is classified as held for sale and the date that the asset is derecognized.
Intangible assets	i. Intangible assets: Separately acquired intangible assets are measured on initial recognition at cost including directly attributable costs. Intangible assets acquired in a business combination are measured at fair value at the acquisition date. Expenditures relating to internally generated intangible assets, excluding capitalized development costs, are recognized in profit or loss when incurred. Intangible assets with a finite useful life are amortized over their useful life and reviewed for impairment whenever there is an indication that the asset may be impaired. The amortization period and the amortization method for an intangible asset are reviewed at least at each year end.
Impairment of non-financial assets	j. Impairment of non-financial assets: The Company evaluates the need to record an impairment of non-financial assets whenever events or changes in circumstances indicate that the carrying amount is not recoverable. If the carrying amount of non-financial assets exceeds their recoverable amount, the assets are reduced to their recoverable amount. The recoverable amount is the higher of fair value less costs of sale and value in use. In measuring value in use, the expected future cash flows are discounted using a pre-tax discount rate that reflects the risks specific to the asset. The recoverable amount of an asset that does not generate independent cash flows is determined for the cash-generating unit to which the asset belongs. Impairment losses are recognized in profit or loss.
Financial instruments	k. Financial instruments: 1. Financial assets: Financial assets are measured upon initial recognition at fair value plus transaction costs that are directly attributable to the acquisition of the financial assets, except for financial assets measured at fair value through profit or loss in respect of which transaction costs are recorded in profit or loss. The Company classifies and measures debt instruments in the financial statements based on the following criteria: - The Company’s business model for managing financial assets; and - The contractual cash flow terms of the financial asset. a) Debt instruments are measured at amortized cost when: The Company’s business model is to hold the financial assets in order to collect their contractual cash flows, and the contractual terms of the financial assets give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding. After initial recognition, the instruments in this category are measured according to their terms at amortized cost using the effective interest rate method, less any provision for impairment. On the date of initial recognition, the Company may irrevocably designate a debt instrument as measured at fair value through profit or loss if doing so eliminates or significantly reduces a measurement or recognition inconsistency, such as when a related financial liability is also measured at fair value through profit or loss. b) Debt instruments are measured at fair value through profit or loss when: A financial asset which is a debt instrument does not meet the criteria for measurement at amortized cost or at fair value through other comprehensive income. After initial recognition, the financial asset is measured at fair value and gains or losses from fair value adjustments are recognized in profit or loss. c) Equity instruments and other financial assets held for trading: Investments in equity instruments do not meet the above criteria and accordingly are measured at fair value through profit or loss. Other financial assets held for trading such as derivatives, including embedded derivatives separated from the host contract, are measured at fair value through profit or loss unless they are designated as effective hedging instruments. Dividends from investments in equity instruments are recognized in profit or loss when the right to receive the dividends is established. 2. Derecognition of financial assets: A financial asset is derecognized only when: - The contractual rights to the cash flows from the financial asset have expired; - The Company has transferred substantially all the risks and rewards deriving from the contractual rights to receive cash flows from the financial asset or has neither transferred nor retained substantially all the risks and rewards of the asset, but has transferred control of the asset; or - The Company has retained its contractual rights to receive cash flows from the financial asset but has assumed a contractual obligation to pay the cash flows in full without material delay to a third party. 3. Financial liabilities: a) Financial liabilities measured at amortized cost: Financial liabilities are initially recognized at fair value less transaction costs that are directly attributable to the issue of the financial liability. After initial recognition, the Company measures all financial liabilities at amortized cost using the effective interest rate method, except for financial liabilities at fair value through profit or loss such as derivatives. b) Financial liabilities measured at fair value through profit or loss: At initial recognition, the Company measures financial liabilities that are not measured at amortized cost at fair value. Transaction costs are recognized in profit or loss. After initial recognition, changes in fair value are recognized in profit or loss. 4. Derecognition of financial liabilities: A financial liability is derecognized only when it is extinguished, that is when the obligation specified in the contract is discharged or cancelled or expires. A financial liability is extinguished when the debtor discharges the liability by paying in cash, other financial assets, goods or services, or is legally released from the liability. 5. Offsetting financial instruments: Financial assets and financial liabilities are offset and the net amount is presented in the statement of financial position if there is a legally enforceable right to set off the recognized amounts and there is an intention either to settle on a net basis or to realize the asset and settle the liability simultaneously. The right of set-off must be legally enforceable not only during the ordinary course of business of the parties to the contract but also in the event of bankruptcy or insolvency of one of the parties. In order for the right of set-off to be currently available, it must not be contingent on a future event, there may not be periods during which the right is not available, or there may not be any events that will cause the right to expire. 6. Compound financial instruments: Convertible debentures which contain both an equity/derivative component and a liability component are separated into two components. This separation is performed by first determining the liability component based on the fair value of an equivalent non-convertible liability. The value of the conversion component is determined to be the residual amount. Directly attributable transaction costs are apportioned between the equity component and the liability component based on the allocation of proceeds to the equity and liability components. 7. Issue of a unit of securities: The issue of a unit of securities involves the allocation of the proceeds received (before issue expenses) to the securities issued in the unit based on the following order: financial derivatives and other financial instruments measured at fair value in each period. Then fair value is determined for financial liabilities that are measured at amortized cost. The proceeds allocated to equity instruments are determined to be the residual amount. Issue costs are allocated to each component pro rata to the amounts determined for each component in the unit.
Research and development expenditures	l. Research and development expenditures: Research expenditures are recognized in profit or loss when incurred. The conditions enabling capitalization of development costs as an asset have not yet been met and, therefore, all development expenditures are recognized in profit or loss when incurred.
Finance income and expenses	m. Finance income and expenses: Finance income and expenses comprise interest income on amounts invested and exchange rate gains and losses. Interest income is recognized as it accrues using the effective interest method. Finance income and expenses derive also from changes in the fair value of financial liabilities measured at fair value through profit or loss. Borrowing costs are recognized in profit or loss using the effective interest method.
Fair value measurement	n. Fair value measurement: Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value measurement is based on the assumption that the transaction will take place in the asset’s or the liability’s principal market, or in the absence of a principal market, in the most advantageous market. The fair value of an asset or a liability is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants act in their economic best interest. Fair value measurement of a non-financial asset takes into account a market participant’s ability to generate economic benefits by using the asset in its highest and best use or by selling it to another market participant that would use the asset in its highest and best use. The Company uses valuation techniques that are appropriate in the circumstances and for which sufficient data are available to measure fair value, maximizing the use of relevant observable inputs and minimizing the use of unobservable inputs. All assets and liabilities measured at fair value or for which fair value is disclosed are categorized into levels within the fair value hierarchy based on the lowest level input that is significant to the entire fair value measurement: Level 1 - Quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 - Inputs other than quoted prices included within Level 1 that are observable directly or indirectly. Level 3 - Inputs that are not based on observable market data (valuation techniques which use inputs that are not based on observable market data).
Taxes on income	o. Taxes on income: Current or deferred taxes are recognized in profit or loss, except to the extent that they relate to items which are recognized in other comprehensive income or equity. 1. Current taxes: A current tax liability is measured using the tax rates and tax laws that have been enacted or substantively enacted by the reporting date as well as adjustments required in connection with the tax liability in respect of previous years. 2. Deferred taxes: Deferred taxes are computed in respect of temporary differences between the carrying amounts in the financial statements and the amounts attributed for tax purposes. Deferred taxes are measured at the tax rate that is expected to apply when the asset is realized, or the liability is settled, based on tax laws that have been enacted or substantively enacted by the reporting date. Deferred tax assets are reviewed at each reporting date and reduced to the extent that it is not probable that they will be utilized. Deductible carryforward losses and temporary differences for which deferred tax assets had not been recognized are reviewed at each reporting date and a respective deferred tax asset is recognized to the extent that their utilization is probable. Taxes that would apply in the event of the disposal of investments in investees have not been taken into account in computing deferred taxes, as long as the disposal of the investments in investees is not probable in the foreseeable future. Also, deferred taxes that would apply in the event of distribution of earnings by investees as dividends have not been taken into account in computing deferred taxes, since the distribution of dividends does not involve an additional tax liability or since it is the Company’s policy not to initiate distribution of dividends from a subsidiary that would trigger an additional tax liability. Taxes on income that relate to distributions of an equity instrument and to transaction costs of an equity transaction are accounted for pursuant to IAS 12, “ Income Taxes Deferred taxes are offset if there is a legally enforceable right to offset a current tax asset against a current tax liability and the deferred taxes relate to the same taxpayer and the same taxation authority.
Share/ADS-based payment transactions	p. Share/ADS-based payment transactions: The Company’s employees and other service providers may receive remuneration in the form of share/ADS-based payments (“Equity-settled transactions”). Equity-settled transactions: The cost of equity-settled transactions with employees is measured at the fair value of the equity instruments granted at grant date. The fair value is determined using an acceptable option pricing model (“OPM”). As for service providers, the cost of the transactions is measured at the fair value of the goods or services received as consideration for equity instruments granted. The cost of equity-settled transactions is recognized in profit or loss together with a corresponding increase in equity during the period in which the performance and/or service conditions are to be satisfied ending on the date on which the relevant employees become entitled to the award (the “Vesting Period”). The cumulative expense recognized for equity-settled transactions at the end of each reporting period until the vesting date reflects the extent to which the Vesting Period has expired and the Company’s best estimate of the number of equity instruments that will ultimately vest. No expense is recognized for awards that do not ultimately vest, except for awards where vesting is conditional upon a market condition, which are treated as vesting irrespective of whether the market condition is satisfied, provided that all other vesting conditions (service and/or performance) are satisfied. If the Company modifies the conditions on which equity-instruments were granted, an additional expense is recognized for any modification that increases the total fair value of the share-based payment arrangement or is otherwise beneficial to the employee/other service provider at the modification date. If a grant of an equity instrument is cancelled, it is accounted for as if it had vested on the cancellation date and any expense not yet recognized for the grant is recognized immediately. However, if a new grant replaces the cancelled grant and is identified as a replacement grant on the grant date, the cancelled and new grants are accounted for as a modification of the original grant, as described above.
Earnings (loss) per share/ADS	q. Earnings (loss) per share/ADS: Earnings (loss) per share or per ADS are calculated by dividing the income (loss) attributable to equity holders of the Company by the weighted number of ordinary shares or ADSs outstanding during the period. Basic loss per ordinary share or ADS includes only ordinary shares or ADSs that were outstanding during the period. Potential ordinary shares or ADSs are included in the computation of diluted loss per ordinary share or per ADS when their conversion increases loss per ordinary share or ADS from continuing operations.
Employee benefit liabilities	r. Employee benefit liabilities: The Company has several employee-benefit plans: 1. Short-term employee benefits: Short-term employee benefits are benefits that are expected to be settled wholly before twelve months after the end of the annual reporting period in which the employees render the related services. These benefits include salaries, paid annual leave, paid sick leave, recreation and social security contributions and are recognized as expenses as the services are rendered. A liability in respect of a cash bonus or a profit-sharing plan is recognized when the Company has a legal or constructive obligation to make such payment as a result of past service rendered by an employee and a reliable estimate of the amount can be made. 2. Post-employment benefits: The plans are normally financed by contributions to insurance companies and classified as defined contribution plans or as defined benefit plans. The Company has defined contribution plans to its employees according to the specific laws per country.
Provisions	s. Provisions: A provision in accordance with IAS 37, “ Provisions, Contingent Liabilities and Contingent Assets Following are the types of provisions included in the financial statements: Legal claims: A provision for claims is recognized when the Company has a present legal or constructive obligation as a result of a past event, it is more likely than not that an outflow of resources embodying economic benefits will be required by the Company to settle the obligation and a reliable estimate can be made of the amount of the obligation.
Leases	t. Leases: The Company elected to apply the provisions of IFRS 16, “ Leases The accounting policy for leases applied effective from January 1, 2019, is as follows: The Company accounts for a contract as a lease when the contract terms convey the right to control the use of an identified asset for a period of time in exchange for consideration. 1. The Company as a lessee: For leases in which the Company is the lessee, the Company recognizes on the commencement date of the lease a right-of-use asset and a lease liability, excluding leases whose term is up to 12 months and leases for which the underlying asset is of low value. For these excluded leases, the Company has elected to recognize lease payments as an expense in profit or loss on a straight-line basis over the lease term (see Note 9). In measuring the lease liability, the Company has elected to apply the practical expedient in IFRS 16 and separates the lease components from the non-lease components (such as management and maintenance services, etc.) included in a single contract. On the commencement date, the lease liability includes all unpaid lease payments discounted at the interest rate implicit in the lease, if that rate can be readily determined, or otherwise using the Company’s incremental borrowing rate. After the commencement date, the Company measures the lease liability using the effective interest rate method. On the commencement date, the right-of-use asset is recognized in an amount equal to the lease liability plus lease payments already made on or before the commencement date and initial direct costs incurred. The right-of-use asset is measured applying the cost model and depreciated over the shorter of its useful life and the lease term. The Company tests for impairment of the right-of-use asset whenever there are indications of impairment pursuant to the provisions of IAS 36, “ Impairment of Assets 2. Lease extension and termination options: A non-cancelable lease term includes both the periods covered by an option to extend the lease when it is reasonably certain that the extension option will be exercised, and the periods covered by a lease termination option when it is reasonably certain that the termination option will not be exercised. In the event of any change in the expected exercise of the lease extension option or in the expected non-exercise of the lease termination option, the Company remeasures the lease liability based on the revised lease term using a revised discount rate as of the date of the change in expectations. The total change is recognized in the carrying amount of the right-of-use asset until it is reduced to zero, and any further reductions are recognized in profit or loss. 3. Lease modifications: If a lease modification does not reduce the scope of the lease and does not result in a separate lease, the Company remeasures the lease liability based on the modified lease terms using a revised discount rate as of the modification date and records the change in the lease liability as an adjustment to the right-of-use asset. If a lease modification reduces the scope of the lease, the Company recognizes a gain or loss arising from the partial or full reduction of the carrying amount of the right-of-use asset and the lease liability. The Company subsequently remeasures the carrying amount of the lease liability according to the revised lease terms, at the revised discount rate as of the modification date and records the change in the lease liability as an adjustment to the right-of-use asset. The accounting policy for leases applied until December 31, 2018, is as follows: The criteria for classifying leases as finance or operating leases depend on the substance of the agreements and are made at the inception of the lease in accordance with the following principles as set out in IAS 17, “ Leases The Company as lessee: Operating leases: Leases in which substantially all the risks and rewards of ownership of the leased asset are not transferred to the Company are classified as operating leases. Lease payments are recognized as an expense in profit or loss on a straight-line basis over the lease term.

Significant Accounting Polici_2

Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2020
Disclosure of significant accounting policies [text block] [Abstract]
Schedule of depreciation is calculated on a straight-line basis over the useful life	% Mainly % Lab equipment 6-50 33 Computers 33-50 33 Office furniture and equipment 20-33 25 Motor vehicles 55 - Leasehold improvements see below -

Discontinued Operations (Tables

Discontinued Operations (Tables)	12 Months Ended
	Dec. 31, 2020
Disclosure of discontinued operations [text block] [Abstract]
Schedule of cash flows provided by (used in) the discontinued operations	Year ended December 31, 2020 2019 Operating activities $ - $ (1,024 ) Investing activities - 724 Financing activities $ - $ -

Cash (Tables)

Cash (Tables)	12 Months Ended
	Dec. 31, 2020
Disclosure of Cash [Abstract]
Schedule of cash	December 31, 2020 2019 Cash for immediate withdrawal - in USD $ 1,878 $ 760 Cash for immediate withdrawal - in NIS 68 110 $ 1,946 $ 870

Other Accounts Receivable (Tabl

Other Accounts Receivable (Tables)	12 Months Ended
	Dec. 31, 2020
Disclosure of Other Accounts Receivable [Abstract]
Schedule of other accounts receivable	December 31, 2020 2019 Government authorities $ 103 $ 41 Other receivables 183 23 Prepaid expenses 308 11 $ 594 $ 75

Property and Equipment, Net (Ta

Property and Equipment, Net (Tables)	12 Months Ended
	Dec. 31, 2020
Discourse of Property and Equipment, Net [Abstract]
Disclosure of detailed information about property, plant and equipment [text block]	Assets owned and used by the Company Right-of- Computers Lab equipment Office furniture and equipment Leasehold improvements Motor vehicles Leasehold office Total Cost: Balance at January 1, 2020 $ 20 $ 12 $ 23 $ 29 $ - $ 193 $ 277 Effect of non-application of IFRS 16 - - - - - (193 ) (193 ) Purchases - - - - - - - Disposals - - - (29 ) - - (29 ) Balance at December 31, 2020 20 12 23 - - - 55 Accumulated depreciation: Balance at January 1, 2020 15 12 11 7 57 102 Effect of non-application of IFRS 16 - - - - - (57 ) (57 ) Depreciation 4 - 2 2 - 7 Disposals - - - (9 ) - - (9 ) Balance at December 31, 2020 19 12 13 - - - 44 Depreciated cost at December 31, 2020 1 - 10 - - - 11 Balance at January 1, 2019 66 2,004 134 29 8 - 2,241 Effect of non-application of IFRS 16 - - - - - 193 193 Purchases 1 - - - - - 1 Disposals (47 ) (1,992 ) (111 ) - (8 ) - (2,158 ) Balance at December 31, 2019 20 12 23 29 - 193 227 Accumulated depreciation: Balance at January 1, 2019 16 97 16 4 1 - 134 Effect of non-application of IFRS 16 - - - - - 57 57 Depreciation 10 102 53 3 2 - 122 Disposals (11 ) (187 ) (10 ) - (3 ) - (211 ) Balance at December 31, 2019 15 12 11 7 - 57 102 Depreciated cost at December 31, 2019 $ 5 $ - $ 12 $ 22 $ - $ 136 $ 175

Trade Payables (Tables)

Trade Payables (Tables)	12 Months Ended
	Dec. 31, 2020
Disclosure of Trade Payables [Abstract]
Schedule of trade payables	December 31, 2020 2019 Accrued expenses $ 279 $ 525 Open debts 277 339 $ 556 $ 864

Other Accounts Payable (Tables)

Other Accounts Payable (Tables)	12 Months Ended
	Dec. 31, 2020
Disclosure of Other Accounts Payable [Abstract]
Schedule of other accounts payable	December 31, 2020 2019 Employees and payroll accruals $ 20 $ 68 Accrued vacation 14 40 $ 34 $ 108

Financial Instruments (Tables)

Financial Instruments (Tables)	12 Months Ended
	Dec. 31, 2020
Disclosure of Financial Instruments [Abstract]
Schedule of financial assets and financial liabilities	December 31, 2020 2019 Financial assets: Cash and restricted deposits $ 1,956 $ 904 1,956 904 Financial liabilities: Current financial liabilities carried at amortized cost 188 972 Credit from others, including short-term lease liability - 67 Warrants liability 353 7 Lease liability - 94 $ 541 $ 1,140
Schedule of hereinafter are the ranges	The price of the ADS as of the valuation date ($) 164.5-238 The exercise price of the option (*) ($) 490 The expected volatility of the price of the ADS (%) 79.2-116.1 The risk-free interest rate for the option contractual term (%) 1.97-2.52 The expected dividends over the option’s expected term (%) 0 Maturity date November 23, 2019
Schedule of reconciliation of fair value measurements	Balance at January 1, 2018 $ - Issuance at November 23, 2018 745 Net change in fair value of the conversion component designated at fair value through profit or loss (468 ) Balance at December 31, 2018 277 Net change in fair value of the conversion component designated at fair value through profit or loss (82 ) Conversion of the proportional part out of the conversion component (195 ) Balance at December 31, 2019 $ -
Schedule of warrants fair value using Black–Scholes OPM	December 31, March 23, Dividend yield (%) 0 0 Expected volatility (%) 132 122.01 Risk-free interest rate (%) 0.38 0.38 Underlying Share Price ($) 3.625 30.1 Exercise price ($) 24.5 24.5 Warrants fair value ($) 2.22 25.2

Employee Benefit Liabilities (T

Employee Benefit Liabilities (Tables)	12 Months Ended
	Dec. 31, 2020
Disclosure of Employee Benefit Liabilities [Abstract]
Schedule of defined contribution plans	Year ended 2020 2019 2018 Expenses in respect of defined contribution plans $ 52 $ 50 $ 65

Equity (Tables)

Equity (Tables)	12 Months Ended
	Dec. 31, 2020
Disclosure of Equity [Abstract]
Disclosure of classes of share capital [text block]	December 31, December 31, Authorized Issued and outstanding Authorized Issued and outstanding Number of shares Ordinary shares 1,800,000,000 145,148,593 15 ,000,000 11,439,401
Schedule of issued and outstanding share capital	Number of Balance at January 1, 2020 11,439,401 Issue of share capital - 2020 Financing Rounds (Note 17e) 125,375,916 Conversion of Warrants (Note 17e) 8,333,276 Balance at December 31, 2020 145,148,593
Disclosure of indirect measurement of fair value of goods or services received, share options granted during period [text block]	March 28, August 22, December 31, Dividend yield (%) 0 0 0 Expected volatility (%) 70.12 84.97 189 Risk-free interest rate (%) 2.18 1.48 0.17 Expected life of Warrants (years) 3 2.58 1.24 Warrants fair value ($) 1.41 1.01 0.37
Schedule of reconciliation of the fair value measurements	Balance of liability due to Warrants at January 1, 2020 $ 7 Reclassification of warrants to liability 464 Net change in fair value of the Warrant designated at fair value through profit or loss (468 ) Balance of liability due to Warrants at December 31, 2020 $ 3
Level 3 [Member]
Disclosure of Equity [Abstract]
Schedule of reconciliation of the fair value measurements	Balance at January 1, 2020 $ - Issuance at April 3, 2020 $ 1,250 Net change in fair value of the Series B warrants designated at fair value through profit or loss 172 Conversion part of Series B warrants (1,422 ) Balance at December 31, 2020 $ -

Share-Based Payment Transacti_2

Share-Based Payment Transactions (Tables)	12 Months Ended
	Dec. 31, 2020
Discourse of Share-based Payment Transactions [Abstract]
Schedule of expense recognized for services received from employees and other service providers	Year ended December 31, 2020 2019 2018 Research and development expenses $ 69 $ 165 $ 109 General and administrative expenses 22 388 495 $ 91 $ 553 $ 604
Schedule of black-Scholes option pricing model	Dividend yield (%) 0 Expected volatility (%) 76 Risk-free interest rate (%) 2.61 Expected life of share options (years) 10 October 10, December 31, Underlying ADS price 154 78.12 Dividend yield (%) 0 0 Expected volatility (%) 70 73 Risk-free interest rate (%) 1.67 1.91 Expected life of share options (years) 10 9.78
Schedule of share options and weighted average exercise prices of share options	Number of Weighted Number of Weighted 2020 USD USD Share/ADS Options outstanding at the beginning of the year 2,101,402 $ 2.41 15,010 $ 337.40 Share/ADS Options granted during the year - - - - Share/ADS Options forfeited during the year (1,311,402 ) 2.50 (18,734 ) 175.00 Share/ADS Options expired during the year - - - - Share/ADS Options outstanding at the end of the year 790,000 2.41 11,285 168.70 Share/ADS Options exercisable at the end of the year 498,660 3.41 7,120 168.70 2019: Share/ADS Options outstanding at the beginning of the year 890,652 $ 3.00 6,361 $ 432.60 Share/ADS Options granted during the year 1,282,000 1.60 9,157 236.60 Share/ADS Options forfeited during the year (18,750 ) 2.80 (134 ) 392.00 Share/ADS Options expired during the year (52,500 ) 3.80 (375 ) 532.00 Share/ADS Options outstanding at the end of the year 2,101,402 2.41 15,010 337.40 Share/ADS Options exercisable at the end of the year 828,484 3.41 5,918 467.60

Additional Information to the_2

Additional Information to the Items of Profit or Loss (Tables)	12 Months Ended
	Dec. 31, 2020
Disclosure of Additional Information To Items Of Profit Or Loss [Abstract]
Schedule of information to the items of profit or loss	Year ended 2020 2019 2018 a. Research and development expenses Wages and related expenses $ 322 $ 435 $ 667 Share-based payment 69 165 109 Regulatory, professional and other expenses 119 437 595 Research and preclinical studies 139 277 593 Clinical studies - 240 692 Chemistry and formulations - 85 54 649 1,639 2,710 b. General and administrative expenses Wages and related expenses 237 382 761 Share-based payment 22 388 495 Professional and directors’ fees 1,283 1,065 1,154 Business development expenses 58 387 1,323 Regulatory expenses 98 112 72 Office maintenance, rent and other expenses 182 72 198 Investor relations and business expenses 22 63 368 1,902 2,469 4,371 c. Other expenses Impairment of goodwill - - 160 Impairment of investment in associate 742 - - 742 - 160 d. Finance income Net change in fair value of financial liabilities designated at fair value through profit or loss (630 ) (292 ) (468 ) Exchange rate differences, net - (2 ) (303 ) Finance income from the convertible loan - (11 ) (35 ) Intercompany finance income - - (22 ) (630 ) (305 ) (828 ) e. Finance expenses Finance expenses due to the convertible debentures - 536 112 Issue expenses related to convertible component and warrants 835 108 - Exchange rate differences, net 12 - - Interest expense in respect of leases 7 19 - Finance expenses from interest and commissions 18 13 9 $ 872 $ 676 $ 121

Loss Per Share_Ads (Tables)

Loss Per Share/Ads (Tables)	12 Months Ended
	Dec. 31, 2020
Disclosure of Loss Per Share Or Ads [Abstract]
Schedule of shares and loss used in the computation of loss per share	Year ended December 31, 2020 2019 2018 Amounts used in the computation of basic and diluted loss Weighted Loss Weighted Loss Weighted Loss In thousands USD In thousands USD In thousands USD Continuing operations: Basic loss per share 36,143 (3,482 ) 8,580 $ (4,479 ) 6,996 $ (6,534 ) Effect of potential dilutive ordinary shares 964 (468 ) - - 972 (395 ) Diluted loss per share 37,107 (3,950 ) 8,580 (4,479 ) 7,968 (6,929 ) Discontinued operations: Basic and Diluted loss per share - - 8,580 (315 ) 6,996 (1,989 ) Effect of potential dilutive ordinary shares - - - - 972 - Diluted loss per share - $ - 8,580 $ (315 ) 7,968 $ (1,989 )

Transactions and Balances wit_2

Transactions and Balances with Related Parties (Tables)	12 Months Ended
	Dec. 31, 2020
Disclosure of Transactions and Balances With Related Parties [Abstract]
Schedule of balances with related parties	December 31, December 31, Key Other Key Other Current liabilities $ 59 $ - $ 208 $ -
Schedule of transactions with related parties	Year ended 2020 2019 2018 Research and development expenses $ - $ 75 $ 75 General and administrative expenses $ - $ - $ 769
Disclosure of information about key management personnel [text block]	Year ended 2020 2019 2018 Short-term benefits $ 746 $ 948 $ 1,379 Cost of share-based payment $ 91 $ 275 $ 520

General (Details)

General (Details) - USD ($) $ in Thousands	1 Months Ended	12 Months Ended
	Mar. 27, 2017	Dec. 31, 2020	Jul. 31, 2018
Disclosure Of General Explanatory [Abstract]
Initial public offering	$ 13,700
ADS ordinary shares (in Shares)		(140)
Ownership interest, percentage		27.00%
Equity percentage			82.36%
Accumulated deficit		$ 55,188
Cash		$ 7,780

Significant Accounting Polici_3

Significant Accounting Policies (Details)	12 Months Ended
	Dec. 31, 2020
Disclosure of significant accounting policies [text block] [Abstract]
Lease term	12 months

Significant Accounting Polici_4

Significant Accounting Policies (Details) - Schedule of depreciation is calculated on a straight-line basis over the useful life	12 Months Ended
	Dec. 31, 2020
Lab equipment [Member]
Significant Accounting Policies (Details) - Schedule of depreciation is calculated on a straight-line basis over the useful life [Line Items]
Straight-line basis over useful life of assets at annual rates mainly	33.00%
Lab equipment [Member] | Bottom of range [Member]
Significant Accounting Policies (Details) - Schedule of depreciation is calculated on a straight-line basis over the useful life [Line Items]
Straight-line basis over useful life of assets at annual rates	6.00%
Lab equipment [Member] | Top of range [Member]
Significant Accounting Policies (Details) - Schedule of depreciation is calculated on a straight-line basis over the useful life [Line Items]
Straight-line basis over useful life of assets at annual rates	50.00%
Computers [Member]
Significant Accounting Policies (Details) - Schedule of depreciation is calculated on a straight-line basis over the useful life [Line Items]
Straight-line basis over useful life of assets at annual rates mainly	33.00%
Computers [Member] | Bottom of range [Member]
Significant Accounting Policies (Details) - Schedule of depreciation is calculated on a straight-line basis over the useful life [Line Items]
Straight-line basis over useful life of assets at annual rates	33.00%
Computers [Member] | Top of range [Member]
Significant Accounting Policies (Details) - Schedule of depreciation is calculated on a straight-line basis over the useful life [Line Items]
Straight-line basis over useful life of assets at annual rates	50.00%
Office furniture and equipment [Member]
Significant Accounting Policies (Details) - Schedule of depreciation is calculated on a straight-line basis over the useful life [Line Items]
Straight-line basis over useful life of assets at annual rates mainly	25.00%
Office furniture and equipment [Member] | Bottom of range [Member]
Significant Accounting Policies (Details) - Schedule of depreciation is calculated on a straight-line basis over the useful life [Line Items]
Straight-line basis over useful life of assets at annual rates	20.00%
Office furniture and equipment [Member] | Top of range [Member]
Significant Accounting Policies (Details) - Schedule of depreciation is calculated on a straight-line basis over the useful life [Line Items]
Straight-line basis over useful life of assets at annual rates	33.00%
Motor vehicles [Member]
Significant Accounting Policies (Details) - Schedule of depreciation is calculated on a straight-line basis over the useful life [Line Items]
Straight-line basis over useful life of assets at annual rates	55.00%
Leasehold improvements [Member]
Significant Accounting Policies (Details) - Schedule of depreciation is calculated on a straight-line basis over the useful life [Line Items]
Straight-line basis over the useful life of the assets, description	see below

Discontinued Operations (Detail

Discontinued Operations (Details) - USD ($) $ in Thousands	Oct. 03, 2018	Jun. 27, 2019	Apr. 08, 2019	Dec. 31, 2018	Jul. 31, 2018
Disclosure of discontinued operations [text block] [Abstract]
Aggregate loan amount					$ 1,625
Accrued interest percent					9.00%
Converted equity percentage	82.36%
Acquisition amount				$ 160
THR’s acquisition in the amount				$ 273
Amount of income (loss)	$ 2,400	$ 616
Aggregate of additional loan amount			$ 822
Interest percentage			9.00%

Discontinued Operations (Deta_2

Discontinued Operations (Details) - Schedule of cash flows provided by (used in) the discontinued operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Schedule of cash flows provided by (used in) the discontinued operations [Abstract]
Operating activities		$ (1,024)
Investing activities		724
Financing activities

Cash (Details) - Schedule of ca

Cash (Details) - Schedule of cash - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Schedule of cash [Abstract]
Cash for immediate withdrawal - in USD	$ 1,878	$ 760
Cash for immediate withdrawal - in NIS	68	110
Cash	$ 1,946	$ 870

Other Accounts Receivable (Deta

Other Accounts Receivable (Details) - Schedule of other accounts receivable - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Schedule of other accounts receivable [Abstract]
Government authorities	$ 103	$ 41
Other receivables	183	23
Prepaid expenses	308	11
Other accounts receivables	$ 594	$ 75

Convertible Loan (Details)

Convertible Loan (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2020	Mar. 19, 2020	Apr. 30, 2019	Apr. 17, 2018
Convertible Loan (Details) [Line Items]
Convertible loan interest rate			12.00%
Annually interest rate	9.00%
Including interest amount				$ 46
Convertible loan maturity date		Apr. 30, 2019
Convertible Loan Agreement [Member] | Cure Pharmaceutical Holding Corp. [Member]
Convertible Loan (Details) [Line Items]
Convertible loan amount					$ 500
Convertible loan interest rate					9.00%

Investment in Associates and _2

Investment in Associates and Investments in Investees (Details) $ in Thousands	Mar. 15, 2020USD ($)shares	Nov. 29, 2020USD ($)	Mar. 29, 2018USD ($)	Aug. 31, 2016USD ($)	Jun. 15, 2014USD ($)	Dec. 31, 2020USD ($)shares	Mar. 15, 2020₪ / shares	Dec. 31, 2019USD ($)	May 31, 2017USD ($)	Jun. 22, 2016USD ($)	May 31, 2016
Investment in Associates and Investments in Investees (Details) [Line Items]
Percentage of shares issued and outstanding share capital	35.00%
Balance of the investment								$ 0
Sale of shares and assets										$ 10
Aggregated in the total									$ 75
Ordinary shares (in Shares) | shares						(140)
Fair market value	$ 351
Transaction costs	$ 51
Purchase of warrant amount						$ 340
Shareholders amount		$ 30
Issued and outstanding shares, percentage		1.00%
Lara [Member] | Investment Agreement [Member]
Investment in Associates and Investments in Investees (Details) [Line Items]
Investment of related parties					$ 1,500
Initial investment					$ 800
Percentage of shares issued and outstanding share capital					48.00%
Percentage of share capital					27.00%
Outstanding amount owed			$ 104
Lara [Member] | Settlement Agreement [Member]
Investment in Associates and Investments in Investees (Details) [Line Items]
Percentage of share capital											27.00%
Lara [Member] | Transfer Agreement [Member]
Investment in Associates and Investments in Investees (Details) [Line Items]
Capital gain				$ 34
Evero [Member]
Investment in Associates and Investments in Investees (Details) [Line Items]
Percentage of shares issued and outstanding share capital	15.00%
Ordinary shares (in Shares) | shares	5,952,469
Transfer of ordinary shares (in Shares) | shares						9,577
Capital Point [Member]
Investment in Associates and Investments in Investees (Details) [Line Items]
Percentage of shares issued and outstanding share capital	11.00%
Ordinary shares (in Shares) | shares	176,470
Ownership interest, percentage	46.00%
Ordinary shares per value (in New Shekels per share) | ₪ / shares							₪ 0.01

Leases (Details)

Leases (Details) $ in Thousands	Sep. 01, 2020USD ($)	Jul. 10, 2017USD ($)
Disclosure of leases [text block] [Abstract]
Square meters		205
Lease fee		$ 65
Description of lease agreement	The lease expired on July 31, 2020. The Company did not exercise its option to extend the Period until July 31, 2023. On September 1, 2020, the Company entered into a one-year lease agreement (“the 2020 Lease”) with a third party for an area of approximately 100 square meters for the Company’s offices in the district of Tel Aviv, Israel. The Company has an option to extend for an additional five-year term. The Company deemed this option as not-reasonably certain to be renewed. The yearly lease fee was set at approximately $44, linked to the NIS.
Bank guarantee amount	$ 44

Property and Equipment, Net (De

Property and Equipment, Net (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Disclosure of property, plant and equipment [Abstract]
Depreciation expense	$ 7	$ 67

Property and Equipment, Net (_2

Property and Equipment, Net (Details) - Schedule of property and equipment, net - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Computers [Member]
Cost:
Beginning Balance	$ 20	$ 66
Effect of non-application of IFRS 16
Purchases		1
Disposals		(47)
Ending Balance	20	(20)
Accumulated depreciation:
Beginning Balance	15	16
Effect of non-application of IFRS 16
Depreciation	4	10
Disposals		(11)
Ending Balance	19	15
Depreciated cost	1	5
Lab equipment [Member]
Cost:
Beginning Balance	12	2,004
Effect of non-application of IFRS 16
Purchases
Disposals		(1,992)
Ending Balance	12	(12)
Accumulated depreciation:
Beginning Balance	12	97
Effect of non-application of IFRS 16
Depreciation		102
Disposals		(187)
Ending Balance	12	12
Depreciated cost
Office Furniture and Equipment [Member]
Cost:
Beginning Balance	23	134
Effect of non-application of IFRS 16
Purchases
Disposals		(111)
Ending Balance	23	(23)
Accumulated depreciation:
Beginning Balance	11	16
Effect of non-application of IFRS 16
Depreciation	2	53
Disposals		(10)
Ending Balance	13	11
Depreciated cost	10	12
Leasehold improvements [Member]
Cost:
Beginning Balance	29	29
Effect of non-application of IFRS 16
Purchases
Disposals	(29)
Ending Balance		(29)
Accumulated depreciation:
Beginning Balance	7	4
Effect of non-application of IFRS 16
Depreciation	2	3
Disposals	(9)
Ending Balance		7
Depreciated cost		22
Motor vehicles [Member]
Cost:
Beginning Balance		8
Effect of non-application of IFRS 16
Purchases
Disposals		(8)
Ending Balance
Accumulated depreciation:
Beginning Balance		1
Effect of non-application of IFRS 16
Depreciation		2
Disposals		(3)
Ending Balance
Depreciated cost
Leasehold office [Member]
Cost:
Beginning Balance	193
Effect of non-application of IFRS 16	(193)	193
Purchases
Disposals
Ending Balance		(193)
Accumulated depreciation:
Beginning Balance	57
Effect of non-application of IFRS 16	(57)	57
Depreciation
Disposals
Ending Balance		57
Depreciated cost		136
Total [Member]
Cost:
Beginning Balance	277	2,241
Effect of non-application of IFRS 16	(193)	193
Purchases		1
Disposals	(29)	(2,158)
Ending Balance	55	(277)
Accumulated depreciation:
Beginning Balance	102	134
Effect of non-application of IFRS 16	(57)	57
Depreciation	7	122
Disposals	(9)	(211)
Ending Balance	44	102
Depreciated cost	$ 11	$ 175

Trade Payables (Details) - Sche

Trade Payables (Details) - Schedule of trade payables - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Schedule of trade payables [Abstract]
Accrued expenses	$ 279	$ 525
Open debts	277	339
Trade payables	$ 556	$ 864

Other Accounts Payable (Details

Other Accounts Payable (Details) - Schedule of other accounts payable - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Schedule of other accounts payable [Abstract]
Employees and payroll accruals	$ 20	$ 68
Accrued vacation	14	40
Other accounts payable	$ 34	$ 108

Financial Instruments (Details)

Financial Instruments (Details) $ / shares in Units, $ in Thousands	Sep. 08, 2020USD ($)	Jul. 08, 2019	Mar. 19, 2020USD ($)$ / sharesshares	Mar. 28, 2019	Nov. 26, 2018USD ($)	Nov. 23, 2018	Dec. 31, 2020	Dec. 31, 2019USD ($)	Dec. 31, 2018USD ($)	Apr. 17, 2020USD ($)	Jan. 15, 2020USD ($)
Financial Instruments (Details) [Line Items]
Description of Issuance of convertible debentures	The Lender was entitled to a transaction and interest fee of $5 (plus VAT) that was offset from the Credit Facility for the immediately drawn $100 and 5% from any additional withdrawal amount from the Credit Facility. On November 24, 2020, the Loan Amount was fully repaid by the Company.	Since July 8, 2019, up until September 13, 2019, Yorkville converted the rest of the principal outstanding amount under the Convertible Debentures, by converting $100 on July 8, 2019; $450 on July 23, 2019; $375 on August 30, 2019; and $325 on September 13, 2019 - refer to Note 17f for more information. Valuation process and techniques: The Company’s management considers the appropriateness of the valuation methods and inputs and may request that alternative valuation methods are applied to support the valuation arising from the method chosen. The valuation of the Convertible Debentures was set in accordance with IFRS 9 and IAS 32, “Financial Instruments: Presentation” (“IAS 32”). IFRS 9 and IAS 32 determine the accepted method in allocating the consideration received from a bundle of securities. According to the guidelines of IFRS 9 and IAS 32, the allocation is based on the method of the remainder of consideration, when there is a hierarchy regarding the financial instruments measured at fair value and the financial instruments recognized as the remainder of consideration. According to IFRS 9 and IAS 32, the allocation is based on the following hierarchy: - Derivative and other financial instrument measured at fair value through its contractual life. - Financial liabilities and other complex instruments which are not recognized at fair value. - Equity instruments. IFRS 9 and IAS 32 also determine that a derivative which may be settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity’s own equity instruments, will be defined as a financial liability, measured and presented at fair value each period. Accordingly, and as mentioned in the Securities Purchase Agreement, in the event of conversion, the number of shares to be issued is unknown (not fixed). Therefore, according to the definition mentioned above, the conversion component is classified as a financial liability that will be measured at fair value, through profit or loss, as of the Issuance Date and on any following financial reporting date (accordingly, issue expenses related to the derivative will be recorded through profit or loss). The remainder of the consideration will be attributed to the debt component and no consideration will be left to attribute to the equity instrument (issuance of 131 ADSs mentioned above). The valuation of the conversion component of Convertible Debentures was set at fair value, as required in IFRS 9, and in accordance with IFRS 13, “Fair value measurement” (“IFRS 13”) and was categorized as Level 3 by the Company. General Overview of Valuation Approaches used in the Valuation: Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Economic methodology: The convertible component was calculated using the Monte Carlo Simulation Model, an OPM which takes into account the parameters as disclosed below for each period valuated, in which a valuation was performed at (i) the Issuance Date, (ii) each reporting date and (iii) prior to each conversion. Hereinafter are the ranges of the parameters used: The price of the ADS as of the valuation date ($) 164.5-238 The exercise price of the option (*) ($) 490 The expected volatility of the price of the ADS (%) 79.2-116.1 The risk-free interest rate for the option contractual term (%) 1.97-2.52 The expected dividends over the option’s expected term (%) 0 Maturity date November 23, 2019 (*)The lower of $490.00 or 95% of the lowest daily VWAP during the five consecutive trading days immediately preceding the conversion date. Hereinafter is the reconciliation of the fair value measurements (the conversion component of the Convertible Debentures) that are categorized within Level 3 of the fair value hierarchy in financial instruments: Balance at January 1, 2018 $ - Issuance at November 23, 2018 745 Net change in fair value of the conversion component designated at fair value through profit or loss (468) Balance at December 31, 2018 277 Net change in fair value of the conversion component designated at fair value through profit or loss (82) Conversion of the proportional part out of the conversion component (195) Balance at December 31, 2019 $- c.Bridge Loan On January 15, 2020, the Company entered into a bridge loan agreement (the “Bridge Loan”) with a third party, in which the third party lent to the Company $50 (the “Bridge Loan Amount”). On April 17, 2020, the Bridge Loan Amount was fully repaid by the Company, including interest in the amount of $2. Accordingly, the Bridge Loan was terminated with no further effect. d.Line of Credit On September 8, 2020, the Company entered into a certain credit agreement (the “Credit Facility”), with M.R.M. Merchavit Holdings and Management Ltd. (the “Lender”), whereby the Lender agreed to extend a line of credit to the Company in the aggregate amount of $200, or the Credit Amount. According to the terms of the Credit Facility, $100 of the Credit Amount (the “Loan Amount”), was immediately drawn on the date of the Credit Facility, and the remaining $100 was available be drawn on an as-needed basis. The Loan Amount was due upon the earlier of one year from September 8, 2020 or at such time that the Company raised $1,500. The Lender was entitled to a transaction and interest fee of $5 (plus VAT) that was offset from the Credit Facility for the immediately drawn $100 and 5% from any additional withdrawal amount from the Credit Facility. On November 24, 2020, the Loan Amount was fully repaid by the Company. e.Dekel On March 19, 2020, the Company entered into a securities purchase agreement with Dekel Pharmaceutical Ltd. (“Dekel”) pursuant to which Dekel agreed to invest in the Company through a private placement transaction (the “Private Placement”). At the time of the Private Placement, Dekel was considered as a related party to the Company; however, it is no longer a related party to the Company. In connection with the Private Placement, Dekel received convertible promissory notes (the “Notes”), with an aggregate original principal amount of approximately $350, at an aggregate purchase price of $315 to be paid in several tranches spread across a twelve-month period. In addition, the Company issued a warrant to purchase up to 4,490 ADSs of the Company (the “Private Placement Warrant”) and 571 ADSs. The initial tranche of the Private Placement was for a principal amount of $220 at a purchase price of $198. The Notes are unsecured, have a maturity date of March 23, 2021, bear interest at a rate of 12% per annum, and may be converted, at the election of the holder, into ADSs at an initial conversion price of $24.50 per ADS (the “Fixed Conversion Price”), subject to adjustments. After the six-month anniversary of the issuance of the Notes, the conversion price shall be equal to the lower of the Fixed Conversion Price or 70% of the lowest trading price of the ADSs as reported on Nasdaq or any exchange upon which the ADSs or ordinary shares of the Company are traded at such time, for the 20 prior trading days including the day upon which a notice of conversion is received by the Company or its transfer agent. The Private Placement Warrant is exercisable at any time on or after the actual closing date and on or prior to the close of business on the five-year anniversary of the date of issuance, at an initial exercise price of $24.5 per ADS, subject to adjustment. On November 8, 2020, the Notes was terminated and the initial tranche was fully repaid by the Company. General Overview of Valuation Approaches used in the Valuation: Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Economic methodology: The warrants’ fair value was calculated using the Black–Scholes OPM, which takes into account the parameters as disclosed below for each period valuated, in which a valuation was performed at (i) the issuance date, and (ii) each reporting date with the following assumptions: December 31, 2020 March 23, 2020 Dividend yield (%) 0 0 Expected volatility (%) 132 122.01 Risk-free interest rate (%) 0.38 0.38 Underlying Share Price ($) 3.625 30.1 Exercise price ($) 24.5 24.5 Warrants fair value ($) 2.22 25.2 f. Financial risk factors: The Company’s activities expose it to various financial risks such as market risks (foreign currency risk and interest risk), credit risk and liquidity risk. The Company’s comprehensive risk management plan focuses on activities that reduce to a minimum any possible adverse effects on the Company’s financial performance. Risk management is performed by management in accordance with the policies approved by the Company’s board of directors (the “Board”). The Board establishes written principles for the overall risk management activities as well as specific policies with respect to certain exposures to risks such as exchange rate risk, credit risk and the investments of surplus funds. 1. Market risks: Foreign currency risk: The Company is exposed to exchange rate risk resulting from the exposure to different currencies, mainly from transactions in NIS. Exchange rate risk arises from recognized liabilities that are denominated in a foreign currency other than the functional currency. 2. Credit risks: All cash and restricted deposits related to the Company are held in two banks in Israel which are considered financially solid. 3. Liquidity risk: The Company monitors the risk of a shortage of funds on a regular basis and acts to raise funds to satisfy its liabilities. As of December 31, 2020, the Company expects to settle all of its financial liabilities in less than one year. The carrying amounts of cash and restricted deposits, and all other financial assets and liabilities approximate their fair value. Refer to Note 1c for more information.		as part of a financing round (see Note 17e.1), Yorkville agreed to invest $250 by converting $250 of the principal outstanding amount ($1,500) under the Convertible Debentures. As a result of the conversion, the Company issued to Yorkville 1,020 ADSs. In addition, as part of the financing round above-mentioned, the Company issued to Yorkville a warrant to purchase up to 765 ADSs.	In addition, $78 was deducted due to issue expenses, and Yorkville received 131 ADSs of the Company in return to additional commitment fees (valued at $75). Also, an additional fee of $10 was deducted from the $1,500 due to payments to Yorkville’s legal counsels. Two additional tranches of $500 each of the Convertible Debentures shall be purchased by Yorkville conditional on the passage of time and/or certain triggering events as disclosed in the Securities Purchase Agreement. If the Company will not comply with the triggering events mentioned, the Company will be deemed to be in default pursuant to the terms, and inter alia, the interest on the Convertible Debentures will accrue up to a rate of 15% per annum. The Company shall pay Yorkville additional commitment fees upon issuance of each such tranche, to be paid at the Company’s option in cash or ADSs of the Company. From and after the date of issuance of the Convertible Debentures, the outstanding principal, together with accrued and unpaid interest, will be convertible, at the option of Yorkville, into the Company’s ADSs at the lower of $7.00 or 95% of the lowest daily volume-weighted average price (“VWAP”) during the five consecutive trading days immediately preceding the conversion date.	the Company entered into a securities purchase agreement (the “Securities Purchase Agreement”) and a registration rights agreement with YA II PN Ltd. (“Yorkville”), a fund managed by Yorkville Advisors Global L.P., for the sale in a private placement of up to $2,500 in principal amount of unsecured convertible debentures (the “Convertible Debentures”). Interest on the Convertible Debentures will accrue at a rate of 5% per annum and can be repaid in cash with an addition of an 10% redemption premium upon the maturity date of the Convertible Debentures, being 12 months from the issuance of each Convertible Debenture.
Convertible debentures issued					$ 1,500
Consecutive trading days							(*)The lower of $490.00 or 95% of the lowest daily VWAP during the five consecutive trading days immediately preceding the conversion date. Hereinafter is the reconciliation of the fair value measurements (the conversion component of the Convertible Debentures) that are categorized within Level 3 of the fair value hierarchy in financial instruments: Balance at January 1, 2018 $ - Issuance at November 23, 2018 745 Net change in fair value of the conversion component designated at fair value through profit or loss (468) Balance at December 31, 2018 277 Net change in fair value of the conversion component designated at fair value through profit or loss (82) Conversion of the proportional part out of the conversion component (195) Balance at December 31, 2019 $- c.Bridge Loan On January 15, 2020, the Company entered into a bridge loan agreement (the “Bridge Loan”) with a third party, in which the third party lent to the Company $50 (the “Bridge Loan Amount”). On April 17, 2020, the Bridge Loan Amount was fully repaid by the Company, including interest in the amount of $2. Accordingly, the Bridge Loan was terminated with no further effect. d.Line of Credit On September 8, 2020, the Company entered into a certain credit agreement (the “Credit Facility”), with M.R.M. Merchavit Holdings and Management Ltd. (the “Lender”), whereby the Lender agreed to extend a line of credit to the Company in the aggregate amount of $200, or the Credit Amount. According to the terms of the Credit Facility, $100 of the Credit Amount (the “Loan Amount”), was immediately drawn on the date of the Credit Facility, and the remaining $100 was available be drawn on an as-needed basis. The Loan Amount was due upon the earlier of one year from September 8, 2020 or at such time that the Company raised $1,500. The Lender was entitled to a transaction and interest fee of $5 (plus VAT) that was offset from the Credit Facility for the immediately drawn $100 and 5% from any additional withdrawal amount from the Credit Facility. On November 24, 2020, the Loan Amount was fully repaid by the Company. e.
Bridge loan amount											$ 50
Interest payable										$ 2
Aggregate amount or credit amount	$ 200
Credit facility amount	100
Credit Facility and remaining available drawn amount	$ 100
Loan amount due term	1 year
Loan amount raised	$ 1,500
Cash paid for principal amount			$ 350
Purchase price			$ 315					$ 1	$ 17
Issued of warrant (in Shares) | shares			4,490
Maturity date			The Notes are unsecured, have a maturity date of March 23, 2021, bear interest at a rate of 12% per annum, and may be converted, at the election of the holder, into ADSs at an initial conversion price of $24.50 per ADS (the “Fixed Conversion Price”), subject to adjustments.
Interest rate			12.00%
Initial conversion price (in Dollars per share) | $ / shares			$ 24,500
Conversion Price (in Dollars per share) | $ / shares			$ 0.70
Warrants exercise price			24.5	245
Private Placement [Member]
Financial Instruments (Details) [Line Items]
Cash paid for principal amount			$ 220
Purchase price			$ 198
ADSs [Member]
Financial Instruments (Details) [Line Items]
Issued of warrant (in Shares) | shares			571

Financial Instruments (Detail_2

Financial Instruments (Details) - Schedule of financial assets and financial liabilities - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Financial assets:
Cash and restricted deposits	$ 1,956	$ 904
Financial assets	1,956	904
Financial liabilities:
Current financial liabilities carried at amortized cost	188	972
Credit from others, including short-term lease liability		67
Warrants liability	353	7
Lease liability		94
Financial liabilities	$ 541	$ 1,140

Financial Instruments (Detail_3

Financial Instruments (Details) - Schedule of hereinafter are the ranges	12 Months Ended
	Dec. 31, 2020$ / shares
Financial Instruments (Details) - Schedule of hereinafter are the ranges [Line Items]
The exercise price of the option ($) (in Dollars per share)	$ 490
The expected dividends over the option’s expected term (%)	0.00%
Minimum [Member]
Financial Instruments (Details) - Schedule of hereinafter are the ranges [Line Items]
The price of the ADS as of the valuation date ($)	164.5
The expected volatility of the price of the ADS (%)	79.20%
The risk-free interest rate for the option contractual term (%)	1.97%
Maximum [Member]
Financial Instruments (Details) - Schedule of hereinafter are the ranges [Line Items]
The price of the ADS as of the valuation date ($)	238
The expected volatility of the price of the ADS (%)	116.10%
The risk-free interest rate for the option contractual term (%)	2.52%

Financial Instruments (Detail_4

Financial Instruments (Details) - Schedule of reconciliation of fair value measurements - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Schedule of reconciliation of fair value measurements [Abstract]
Beginning Balance	$ 277
Issuance at November 23, 2018		745
Net change in fair value of the conversion component designated at fair value through profit or loss	(82)	(468)
Conversion of the proportional part out of the conversion component	(195)
Ending Balance		$ 277

Financial Instruments (Detail_5

Financial Instruments (Details) - Schedule of warrants fair value using Black–Scholes OPM	1 Months Ended	12 Months Ended
	Mar. 23, 2020$ / shares	Dec. 31, 2020$ / shares
Schedule of warrants fair value using Black–Scholes OPM [Abstract]
Dividend yield (%)	0.00%	0.00%
Expected volatility (%)	122.01%	132.00%
Risk-free interest rate (%)	0.38%	0.38%
Underlying Share Price ($) (in Dollars per share)	$ 30.1	$ 3.625
Exercise price ($)	24.5	24.5
Warrants fair value ($) (in Dollars per share)	$ 25.2	$ 2.22

Employee Benefit Liabilities (D

Employee Benefit Liabilities (Details) - Schedule of defined contribution plans - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Schedule of defined contribution plans [Abstract]
Expenses in respect of defined contribution plans	$ 52	$ 50	$ 65

Taxes on Income (Details)

Taxes on Income (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2018	Dec. 31, 2019
Disclosure of income tax [Abstract]
Israeli corporate income tax	23.00%	2019.00%
Carry forward tax losses, total	$ 43,000		$ 39,000

Contingent Liabilities, Commi_2

Contingent Liabilities, Commitments, Claims and Liens (Details) - USD ($) $ in Thousands	Aug. 11, 2020	Nov. 13, 2019	Aug. 13, 2018	Apr. 11, 2017	Oct. 31, 2019	May 31, 2015	Jul. 14, 2019	Feb. 29, 2016
Disclosure of commitments and contingent liabilities [text block] [Abstract]
Funds for research development								$ 62
Commitment payments, description						(i) $25 upon the successful completion of preclinical trials (which milestone was met in November 2016; this milestone was paid in cash in March 2017); (ii) $75 upon the successful completion of a Phase I/IIa trial; and (iii) $75 upon the earlier of generating net revenues of at least $200 from the commercialization of the technology or the approval of the U.S. Food and Drug Administration or the European Medicines Agency, of a drug based on the licensed assets. In each case, and subject to the Company’s discretion, the respective milestone payments are payable in cash or equity based on a price per ordinary share of NIS 0.5. The royalty payments are 8% for commercialization and 35% pursuant to a sub-license of the licensed assets. The patent expiration dates of any patents maturing from this application would likely be 2029.
Total annual investment							$ 350
Additional milestone amount		$ 75
License agreement pay amount				$ 122
Total agreement estimating in amount			$ 835	$ 776
Letter of demand received from former service					$ 85
Capital proposed to deposit	$ 1,500

Equity (Details)

Equity (Details) $ in Thousands

Oct. 16, 2020shares

Oct. 01, 2020shares

Apr. 01, 2020

Sep. 13, 2019USD ($)shares

Nov. 20, 2020USD ($)shares

Sep. 17, 2020

Dec. 03, 2019

Aug. 22, 2019USD ($)shares

Mar. 28, 2019

Dec. 31, 2020USD ($)shares

Mar. 19, 2020

Dec. 31, 2019shares

Aug. 30, 2019USD ($)

Jul. 23, 2019USD ($)

Jul. 08, 2019USD ($)

Mar. 31, 2019USD ($)

Equity (Details) [Line Items]

Description of american depositary shares

The Bank of New York Mellon, as depositary, registers and delivers the Company’s ADSs. Each ADS represents one hundred and forty (140) ordinary shares. Each ADS will also represent any other securities, cash or other property which may be held by the depositary.

Description of reverse share split

the Company convened a special general meeting of its shareholders, whereby the shareholders approved, inter alia, (i) an increase to the Company’s share capital from 500,000,000 ordinary shares to 750,000,000 ordinary shares; and (ii) a reverse split of the Company’s share capital up to a ratio of 20:1 (the “Reverse Split”).

Description of public offering

The total gross proceeds to the Company from the Offerings was $2,000, not including the conversion above mentioned by Yorkville and net of issue expenses in the total amount of $356, out of which $248 were attributed to the Registered Direct Offering and the additional $108 were attributed to the Warrants. The closing of the sale of the ADSs and Warrants occurred on April 1, 2019.

Warrants exercise price

245

24.5

Resale of underlying the warrants

459,640

Purchase agreement, description

(i) one ADS and (ii) two warrants to purchase one ADS each, at a purchase price of $5.02 per unit (“November 2020 Warrants”). The November 2020 Warrants have an exercise price of $5.02 per ADS, will be exercisable upon issuance and will expire five years from the date of issuance.

Gross proceeds | $

$ 4,200

Shares issued

835,447

145,148,593

11,439,401

Outstanding Convertible debentures | $

$ 325

$ 375

$ 450

$ 100

Total consideration of conversion | $

$ 250

$ 1,507

Purchase Agreement [Member]

Equity (Details) [Line Items]

Purchase agreement, description

the Company entered into definitive securities purchase agreements with institutional investors to purchase an aggregate 14,286 of the Company’s ADSs, representing 2,000,040 ordinary shares, at a purchase price of $87.5 per ADS in a registered direct offering (the “December Registered Direct Offering”). The proceeds to the Company from the December Registered Direct Offering were $1,029, net of issue expenses in the total amount of $221.

(i) 9,184 of the Company’s ADSs, representing 1,285,760 ordinary shares, at a purchase price of $245 per ADS, in a registered direct offering (the “Registered Direct Offering”); and (ii) warrants to purchase up to 6,888 ADSs, representing 964,320 ordinary shares, with an initial exercise price of $245 per ADS (the “Warrants”), in a concurrent private placement (the “March 2019 Financing Round” and, together with the Registered Direct Offering, the “Offerings”). The March 2019 Financing Round included an investment from Yorkville that was made by converting $250 of the principal outstanding amount under the Convertible Debentures (see Note 13b).

April 2020 Purchase Agreement [Member]

Equity (Details) [Line Items]

Purchase agreement, description

the Company entered into a definitive securities purchase agreement (the “April 2020 Purchase Agreement”) with institutional investors to purchase of 59,524 units, each consisting of (i) one pre-funded warrant to purchase one ADS and (ii) one Series B warrant to purchase one ADS, at a purchase price of $20.993 per unit. The Series B warrants have an exercise price of $30.10 per ADS, are exercisable upon issuance and expire five years from the date of issuance. The offering resulted in gross proceeds to the Company of approximately $1,250. The closing of the sale of the securities took place on April 3, 2020. After the closing of the April 2020 Purchase Agreement and until the Approval Date, all pre-funded warrants were exercised. In addition, 59,524 of the Series B warrants were exercised pursuant to a cashless exercise mechanism as described in the April 2020 Purchase Agreement for no further consideration to the Company. As of the Approval Date, all Series B warrants were exercised.

Minimum [Member]

Equity (Details) [Line Items]

Ordinary shares issued

750,000,000

Maximum [Member]

Equity (Details) [Line Items]

Ordinary shares issued

1,800,000,000

ADSs [Member]

Equity (Details) [Line Items]

Ordinary shares issued

140

1,141,140

Resale of underlying the warrants

6,566

Fair value of warrants | $

$ 464

Shares issued

8,151

Equity (Details) - Schedule of

Equity (Details) - Schedule of share capital - shares	Dec. 31, 2020	Dec. 31, 2019
Schedule of share capital [Abstract]
Ordinary shares, Authorized	1,800,000,000	15,000,000
Ordinary shares, Issued and outstanding	145,148,593	11,439,401

Equity (Details) - Schedule o_2

Equity (Details) - Schedule of issued and outstanding share capital	12 Months Ended
	Dec. 31, 2020shares
Schedule of issued and outstanding share capital [Abstract]
Number of ordinary shares, Balance at January 1, 2020	11,439,401
Number of ordinary shares, Issue of share capital - 2020 Financing Rounds (Note 17e)	125,375,916
Number of ordinary shares, Conversion of Warrants (Note 17e)	8,333,276
Number of ordinary shares, Balance at December 31, 2020	145,148,593

Equity (Details) - Schedule o_3

Equity (Details) - Schedule of warrants fair value was calculated using the Black-Scholes OPM - $ / shares	1 Months Ended		12 Months Ended
	Aug. 22, 2019	Mar. 28, 2019	Dec. 31, 2020
Schedule of warrants fair value was calculated using the Black-Scholes OPM [Abstract]
Dividend yield (%)	0.00%	0.00%	0.00%
Expected volatility (%)	84.97%	70.12%	189.00%
Risk-free interest rate (%)	1.48%	2.18%	0.17%
Expected life of Warrants (years)	2 years 211 days	3 years	1 year 87 days
Warrants fair value ($) (in Dollars per share)	$ 1.01	$ 1.41	$ 0.37

Equity (Details) - Schedule o_4

Equity (Details) - Schedule of reconciliation of the fair value measurements $ in Thousands	12 Months Ended
	Dec. 31, 2020USD ($)
Schedule of reconciliation of the fair value measurements [Abstract]
Balance of liability due to Warrants at January 1, 2020	$ 7
Reclassification of warrants to liability	464
Net change in fair value of the Warrant designated at fair value through profit or loss	(468)
Balance of liability due to Warrants at December 31, 2020	$ 3

Equity (Details) - Schedule o_5

Equity (Details) - Schedule of reconciliation of the fair value measurements - Level 3 [Member] $ in Thousands	12 Months Ended
	Dec. 31, 2020USD ($)
Equity (Details) - Schedule of reconciliation of the fair value measurements [Line Items]
Balance at January 1, 2020
Issuance at April 3, 2020	1,250
Net change in fair value of the Series B warrants designated at fair value through profit or loss	172
Conversion part of Series B warrants	(1,422)
Balance at December 31, 2020

Share-Based Payment Transacti_3

Share-Based Payment Transactions (Details) - USD ($) $ / shares in Units, $ in Thousands	Oct. 10, 2019	Mar. 12, 2019	Dec. 31, 2020	Dec. 31, 2019	Nov. 13, 2019
Share-Based Payment Transactions (Details) [Line Items]
Board reserved shares (in Shares)					950,000
Share Options reserved (in Shares)					2,200,000
Available for grant shares (in Shares)				1,410,000
Stock option (in Shares)	1,418,060			300,020
Board of directors approved and granted (in Shares)	10,129			2,143
Share option par value				$ 210
Stock option description				Out of the 7,986 ADS Options that were granted, 1,395 ADS Options didn’t require the General Meeting’s approval. The date of commencement for all ADS Options granted, the date on which the vesting started, was the Grant Date.
Fair value description			The fair value of the ADSs options approved on October 10, 2019 by the Board, and on January 15, 2020 at the General Meeting (valuated as of December 31, 2019) was set at $114.1 and $51.1, per ADS Option, respectively.
Weighted average fair value of share options granted one				$ 0.6
Weighted average fair value of share options granted two				$ 84
Weighted average remaining contractual life			5 years	7 years 171 days
Bottom of range [member]
Share-Based Payment Transactions (Details) [Line Items]
Share option par value			$ 1.50	$ 1.50
Top of range [member]
Share-Based Payment Transactions (Details) [Line Items]
Share option par value			$ 6.43	6.20
ADSs [Member]
Share-Based Payment Transactions (Details) [Line Items]
Stock option (in Shares)		164,000	140
Board of directors approved and granted (in Shares)		1,171
Share option par value		$ 420
Fair value of option (in Dollars)			$ 224
ADSs [Member] | Bottom of range [member]
Share-Based Payment Transactions (Details) [Line Items]
Share option par value			$ 210	210
ADSs [Member] | Top of range [member]
Share-Based Payment Transactions (Details) [Line Items]
Share option par value			$ 900.20	$ 868

Share-Based Payment Transacti_4

Share-Based Payment Transactions (Details) - Schedule of expense recognized for services received from employees and other service providers - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Schedule of expense recognized for services received from employees and other service providers [Abstract]
Research and development expenses	$ 69	$ 165	$ 109
General and administrative expenses	22	388	495
Expenses due to share-based compensation	$ 91	$ 553	$ 604

Share-Based Payment Transacti_5

Share-Based Payment Transactions (Details) - Schedule of black-Scholes option pricing model - $ / shares	Oct. 10, 2019	Mar. 23, 2020	Dec. 31, 2020	Dec. 31, 2019
Share-Based Payment Transactions (Details) - Schedule of black-Scholes option pricing model [Line Items]
Dividend yield (%)			0.00%
Expected volatility (%)			76.00%
Risk-free interest rate (%)			2.61%
Expected life of share options (years)			10 years
Underlying ADS price (in Dollars per share)		$ 30.1	$ 3.625
Black scholes ption pricing model [Member]
Share-Based Payment Transactions (Details) - Schedule of black-Scholes option pricing model [Line Items]
Dividend yield (%)	0.00%			0.00%
Expected volatility (%)	70.00%			73.00%
Risk-free interest rate (%)	1.67%			1.91%
Expected life of share options (years)	10 years			9 years 284 days
Underlying ADS price (in Dollars per share)	$ 154			$ 78.12

Share-Based Payment Transacti_6

Share-Based Payment Transactions (Details) - Schedule of share options and weighted average exercise prices of share options - $ / shares	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Share-Based Payment Transactions (Details) - Schedule of share options and weighted average exercise prices of share options [Line Items]
Share/ADS Options outstanding at the beginning of the year	2,101,402	890,652
Share/ADS Options outstanding at the beginning of the year, Weighted average exercise price	$ 2.41	$ 3
Share/ADS Options granted during the year		1,282,000
Share/ADS Options granted during the year, Weighted average exercise price		$ 1.60
Share/ADS Options forfeited during the year	(1,311,402)	(18,750)
Share/ADS Options forfeited during the year, Weighted average exercise price	$ 2.50	$ 2.80
Share/ADS Options expired during the year		(52,500)
Share/ADS Options expired during the year, Weighted average exercise price		$ 3.80
Share/ADS Options outstanding at the end of the year	790,000	2,101,402
Share/ADS Options outstanding at the end of the year, Weighted average exercise price	$ 2.41	$ 2.41
Share/ADS Options exercisable at the end of the year	498,660	828,484
Share/ADS Options exercisable at the end of the year, Weighted average exercise price	$ 3.41	$ 3.41
ADSs [Member]
Share-Based Payment Transactions (Details) - Schedule of share options and weighted average exercise prices of share options [Line Items]
Share/ADS Options outstanding at the beginning of the year	15,010	6,361
Share/ADS Options outstanding at the beginning of the year, Weighted average exercise price	$ 337.40	$ 432.60
Share/ADS Options granted during the year		9,157
Share/ADS Options granted during the year, Weighted average exercise price		$ 236.60
Share/ADS Options forfeited during the year	(18,734)	(134)
Share/ADS Options forfeited during the year, Weighted average exercise price	$ 175	$ 392
Share/ADS Options expired during the year		(375)
Share/ADS Options expired during the year, Weighted average exercise price		$ 532
Share/ADS Options outstanding at the end of the year	11,285	15,010
Share/ADS Options outstanding at the end of the year, Weighted average exercise price	$ 168.70	$ 337.40
Share/ADS Options exercisable at the end of the year	7,120	5,918
Share/ADS Options exercisable at the end of the year, Weighted average exercise price	$ 168.70	$ 467.60

Additional Information to the_3

Additional Information to the Items of Profit or Loss (Details) - Schedule of information to the items of profit or loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
a. Research and development expenses:
Research and development expenses	$ 649	$ 1,639	$ 2,710
b. General and administrative expenses:
General and administrative expenses	1,902	2,469	4,371
c. Other expenses:
Other expenses, net	742		160
Net change in fair value of financial liabilities designated at fair value through profit or loss	(630)	(292)	(468)
Exchange rate differences, net		(2)	(303)
Finance income from the convertible loan		(11)	(35)
Intercompany finance income			(22)
Finance income:	(630)	(305)	(828)
e. Finance expenses:
Finance expenses due to the convertible debentures		536	112
Issue expenses related to convertible component and warrants	835	108
Exchange rate differences, net	12
Interest expense in respect of leases	7	19
Finance expenses from interest and commissions	18	13	9
Finance expenses	872	676	121
Wages and related expenses [Member]
a. Research and development expenses:
Research and development expenses	322	435	667
b. General and administrative expenses:
General and administrative expenses	237	382	761
Share-based payment [Member]
a. Research and development expenses:
Research and development expenses	69	165	109
b. General and administrative expenses:
General and administrative expenses	22	388	495
Regulatory, professional and other expenses [Member]
a. Research and development expenses:
Research and development expenses	119	437	595
Research and preclinical studies [Member]
a. Research and development expenses:
Research and development expenses	139	277	593
Clinical studies [Member]
a. Research and development expenses:
Research and development expenses		240	692
Chemistry and formulations [Member]
a. Research and development expenses:
Research and development expenses		85	54
Professional and directors’ fees [Member]
b. General and administrative expenses:
General and administrative expenses	1,283	1,065	1,154
Business development expenses [Member]
b. General and administrative expenses:
General and administrative expenses	58	387	1,323
Regulatory expenses [Member]
b. General and administrative expenses:
General and administrative expenses	98	112	72
Office maintenance, rent and other expenses [Member]
b. General and administrative expenses:
General and administrative expenses	182	72	198
Investor relations and business expenses [Member]
b. General and administrative expenses:
General and administrative expenses	22	63	368
Impairment of goodwill [Member]
c. Other expenses:
Other expenses, net			160
Capital loss from sale of property and equipment [Member]
c. Other expenses:
Other expenses, net	$ 742

Loss Per Share_Ads (Details) -

Loss Per Share/Ads (Details) - Schedule of shares and loss used in the computation of loss per share - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Continuing operations [Member]
Continuing operations:
Weighted number of shares, Amounts used in the computation of basic and diluted loss per (in Shares)	37,107	8,580	7,968
Amounts used in the computation of basic and diluted loss per	$ (3,950)	$ (4,479)	$ (6,929)
Continuing operations [Member] | ADSs [Member]
Continuing operations:
Weighted number of shares, Amounts used in the computation of basic and diluted loss per (in Shares)	36,143	8,580	6,996
Amounts used in the computation of basic and diluted loss per	$ (3,482)	$ (4,479)	$ (6,534)
Continuing operations [Member] | Ordinary shares [Member]
Continuing operations:
Weighted number of shares, Amounts used in the computation of basic and diluted loss per (in Shares)	964		972
Amounts used in the computation of basic and diluted loss per	$ (468)		$ (395)
Discontinued operations [member]
Continuing operations:
Weighted number of shares, Amounts used in the computation of basic and diluted loss per (in Shares)		8,580	7,968
Amounts used in the computation of basic and diluted loss per		$ (315)	$ (1,989)
Discontinued operations [member] | ADSs [Member]
Continuing operations:
Weighted number of shares, Amounts used in the computation of basic and diluted loss per (in Shares)		8,580	6,996
Amounts used in the computation of basic and diluted loss per		$ (315)	$ (1,989)
Discontinued operations [member] | Ordinary shares [Member]
Continuing operations:
Weighted number of shares, Amounts used in the computation of basic and diluted loss per (in Shares)			972
Amounts used in the computation of basic and diluted loss per

Transactions and Balances wit_3

Transactions and Balances with Related Parties (Details) - Schedule of balances with related parties - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Key management personnel [Member]
Transactions and Balances with Related Parties (Details) - Schedule of balances with related parties [Line Items]
Current liabilities	$ 59	$ 208
Other related parties [Member]
Transactions and Balances with Related Parties (Details) - Schedule of balances with related parties [Line Items]
Current liabilities

Transactions and Balances wit_4

Transactions and Balances with Related Parties (Details) - Schedule of transactions with related parties - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Schedule of transactions with related parties [Abstract]
Research and development expenses		$ 75	$ 75
General and administrative expenses			$ 769

Transactions and Balances wit_5

Transactions and Balances with Related Parties (Details) - Schedule of benefits to key management personnel - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Schedule of benefits to key management personnel [Abstract]
Short-term benefits	$ 746	$ 948	$ 1,379
Cost of share-based payment	$ 91	$ 275	$ 520

Events After The Reporting Da_2

Events After The Reporting Date (Details) - Non-adjusting events after reporting period [member] $ in Thousands	Mar. 04, 2021USD ($)	Mar. 02, 2021shares	Jan. 07, 2021
Events After The Reporting Date (Details) [Line Items]
Subsequent event, description	On March 4, 2021, the Company completed a private offering with several accredited and institutional investors for gross proceeds of $8,150, providing for the issuance of an aggregate of 1,152,628 units, as follows: (a) 916,316 units at a price of $7.07 per unit, consisting of (i) one ADS of the Company, and (ii) a Series A Warrant to purchase an equal number of units purchased (the “2021 Series A Warrant”) and a Series B Warrant (the “2021 Series B Warrant”) to purchase half the number of units (the “Ordinary Warrants”), and (b) 236,312 pre-funded units at a price of $7.069 per unit, consisting of (i) one pre-funded warrant to purchase one ADS and (ii) one 2021 Series A Warrant and one 2021 Series B Warrant.	On March 2, 2021, the general meeting of the Company’s shareholders approved amendments to the Company’s Amended and Restated Articles of Association to eliminate the par value of the Company’s ordinary shares and to increase the Company’s share capital to 3,600,000,000 ordinary shares.	On January 7, 2021, the general meeting of the Company’s shareholders approved the election of Mr. Amnon Ben Shay and Mr. Alon Dayan to serve as external directors of the Company, for a three-year term commencing as of the date of such meeting. b. On March 2, 2021, the general meeting of the Company’s shareholders approved amendments to the Company’s Amended and Restated Articles of Association to eliminate the par value of the Company’s ordinary shares and to increase the Company’s share capital to 3,600,000,000 ordinary shares. c.
Ordinary shares issued | shares		3,600,000,000
Warrants expire period	5 years
Gross proceeds from the offering | $	$ 8,150
ADSs [Member] | Series A Warrant [Member]
Events After The Reporting Date (Details) [Line Items]
Warrants exercise price	7.07
ADSs [Member] | Series B Warrant [Member]
Events After The Reporting Date (Details) [Line Items]
Warrants exercise price	10.60